

Epithelial magnesium transport by TRPM6 is essential for prenatal development and adult survival

Vladimir Chubanov^{1*}, Silvia Ferioli¹, Annika Wisnowsky¹, David G Simmons², Christin Leitzinger³, Claudia Einer³, Wenke Jonas^{4,5}, Yuriy Shymkiv⁶, Harald Bartsch⁷, Attila Braun^{8,9}, Banu Akdogan¹, Lorenz Mittermeier¹, Ludmila Sytik¹, Friedrich Torben¹⁰, Vindi Jurinovic¹¹, Emiel PC van der Vorst¹², Christian Weber^{12,13}, Önder A Yildirim^{14,15}, Karl Sotlar^{7†}, Annette Schürmann^{4,5}, Susanna Zierler¹, Hans Zischka³, Alexey G Ryazanov^{6,16}, Thomas Gudermann^{1,13,17*}

¹Walther-Straub Institute of Pharmacology and Toxicology, Ludwig Maximilian University of Munich, Munich, Germany; ²School of Biomedical Sciences, The University of Queensland, Brisbane, Australia; ³Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum Munich, Neuherberg, Germany; ⁴Department of Experimental Diabetology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany; ⁵German Center for Diabetes Research, Munich, Germany; ⁶Princeton Institute of Life Sciences, Princeton, United States; ⁷Institute of Pathology, Ludwig Maximilian University of Munich, Munich, Germany; ⁸Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Würzburg, Germany; ⁹Department of Vascular Medicine, University Hospital Würzburg, Würzburg, Germany; ¹⁰Genome Analysis Center, Institute of Experimental Genetics, Helmholtz Zentrum Munich, Neuherberg, Germany; ¹¹Institute for Medical Informatics, Biometry and Epidemiology, Ludwig Maximilian University of Munich, Munich, Germany; ¹²Institute for Cardiovascular Prevention, Ludwig Maximilian University of Munich, Munich, Germany; ¹³German Centre for Cardiovascular Research, Munich Heart Alliance, Munich, Germany; ¹⁴Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum Munich, Neuherberg, Germany; ¹⁵German Center for Lung Research, Munich, Germany; ¹⁶Department of Cellular and Molecular Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, United States; ¹⁷Comprehensive Pneumology Center Munich, German Center for Lung Research, Munich, Germany

*For correspondence: vladimir.chubanov@lrz.uni-muenchen.de (VC); thomas.gudermann@lrz.uni-muenchen.de (TG)

Present address: [†]Institute of Pathology, Paracelsus Medical University, Salzburg, Austria

Competing interests: The authors declare that no competing interests exist.

Funding: See page 27

Received: 25 August 2016

Accepted: 13 December 2016

Published: 19 December 2016

Reviewing editor: Richard S Lewis, Stanford University School of Medicine, United States

© Copyright Chubanov et al. This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Abstract Mg²⁺ regulates many physiological processes and signalling pathways. However, little is known about the mechanisms underlying the organismal balance of Mg²⁺. Capitalizing on a set of newly generated mouse models, we provide an integrated mechanistic model of the regulation of organismal Mg²⁺ balance during prenatal development and in adult mice by the ion channel TRPM6. We show that TRPM6 activity in the placenta and yolk sac is essential for embryonic development. In adult mice, TRPM6 is required in the intestine to maintain organismal Mg²⁺ balance, but is dispensable in the kidney. *Trpm6* inactivation in adult mice leads to a shortened lifespan, growth deficit and metabolic alterations indicative of impaired energy balance. Dietary Mg²⁺ supplementation not only rescues all phenotypes displayed by *Trpm6*-deficient adult mice,

but also may extend the lifespan of wildtype mice. Hence, maintenance of organismal Mg^{2+} balance by TRPM6 is crucial for prenatal development and survival to adulthood.

DOI: [10.7554/eLife.20914.001](https://doi.org/10.7554/eLife.20914.001)

Introduction

Mg^{2+} is the most abundant intracellular divalent cation and is essential for the regulation of a broad spectrum of metabolic and signalling pathways (*de Baaij et al., 2015*). In addition, direct association with Mg^{2+} fosters the structural integrity of key metabolites (such as ATP), proteins, lipid membranes and nucleic acids (*de Baaij et al., 2015*) implying that organismal Mg^{2+} deficiency, a surprisingly common condition in humans (*King et al., 2005; Rosanoff et al., 2012*), may be especially harmful during prenatal development and early postnatal life, when the production of and the demand for Mg^{2+} -bound metabolites is particularly high. There is growing evidence to suggest that Mg^{2+} deprivation is accompanied by different types of metabolic, immune, cardiovascular and neurological disorders (*de Baaij et al., 2015*). However, mainly due to the lack of adequate mammalian genetic models, it still remains unclear whether an imbalance in Mg^{2+} metabolism is merely associated with or can directly trigger the latter pathophysiological processes. Furthermore, it has recently been shown that cellular Mg^{2+} fluxes regulate the circadian rhythm and energy balance (*Feeney et al., 2016*), CGRP-mediated osteogenic differentiation (*Zhang et al., 2016*) and synaptic plasticity (*Palcios-Prado et al., 2014*), and that changes in the composition of brain interstitial Mg^{2+} -concentrations participate in the control of the sleep-wake cycle (*Ding et al., 2016*).

The remarkable recent progress in our understanding of the critical role of Mg^{2+} in health and disease contrasts with the dearth of knowledge about the mechanisms governing cellular and organismal Mg^{2+} balance. Approximately 10 plasma membrane Mg^{2+} channels have been proposed (*Quamme, 2010*) indicating a high degree of redundancy. However, quite some controversy surrounds the biological role of many of these proteins, and the question whether there is a central gatekeeper responsible for organismal Mg^{2+} balance has not yet been answered. The kinase-coupled ion channel TRPM7 has been proposed as a ubiquitous, indispensable cellular Mg^{2+} entry pathway (*Schmitz et al., 2003; Chubanov et al., 2004; Ryazanova et al., 2010; Stritt et al., 2016*). However, studies with *Trpm7* gene-deficient mice failed to confirm a corresponding in vivo role of *Trpm7*. Thus, constitutive inactivation of *Trpm7* in mice entailed early embryonic lethality for as yet unknown reasons (*Jin et al., 2008*). Furthermore, tissue-specific deletions of *Trpm7* in mouse embryos affected morphogenesis of internal organs apparently in a Mg^{2+} -independent manner (*Jin et al., 2008, 2012; Sah et al., 2013*). More recently, it was suggested that the Mg^{2+} transporter MagT1 rather than TRPM7 might play a critical role for Mg^{2+} homeostasis in T lymphocytes (*Li et al., 2011*) and probably also in the whole embryo (*Zhou and Clapham, 2009*). Hence, the biological role of TRPM7 requires further clarification.

In the present work, we focussed on the closest TRPM7 relative, TRPM6, because loss-of-function mutations in *TRPM6* cause hypomagnesemia (low Mg^{2+} blood levels) in human infants thought to mainly result from renal Mg^{2+} wasting (*Schlingmann et al., 2002; Walder et al., 2002; Voets et al., 2004*). However, deletion of *Trpm6* in mice has resulted in neural tube closure defects and embryonic death (*Walder et al., 2009*) indicating a direct role of TRPM6 in developmental processes and calling into question the simplistic view on the human *TRPM6* phenotype.

By integrating systematic phenotyping of *Trpm6* gene-modified mice with biochemical analysis, gene expression, metabolomics, and cell biological approaches, we decipher the molecular and organismal roles of TRPM6 in prenatal development and postnatal survival.

Results

TRPM6 function in extraembryonic cells is essential for fetal development

To understand the role of *Trpm6* in prenatal development, we determined the onset of embryonic lethality in *Trpm6* null embryos and investigated the expression pattern of *Trpm6* at this stage. Using a mouse strain carrying a gene-trap mutation in *Trpm6* (*Trpm6* ^{β geo}) (**Table 1**), we found that *Trpm6* ^{β geo/ β geo} embryos were present at embryonic days (e) 8.5–10.5 (**Figure 1A**). However, only

eLife digest A balanced diet contains a variety of minerals such as magnesium ions, which are required for many chemical reactions in our body. A shortage of magnesium ions is linked to many diseases and is thought to be especially harmful to babies in the womb and shortly after birth. Magnesium ion deficiency is widespread in human populations and in the US is thought to affect up to 68% of people.

Despite its prominent role in human health, our understanding of how the body maintains the right balance of magnesium ions remains extremely vague. Magnesium ions can enter and leave a cell by passing through specific types of proteins that form channels in the membrane surrounding the cell. There are thought to be around ten types of these magnesium ion channels in human cells, but we do not know what roles any of them perform in the body. One such channel called TRPM6 may be particularly important because mutations in the gene that encodes this channel can cause magnesium ion deficiency in human infants. However, the loss of TRPM6 in mice disrupts how mouse embryos develop, suggesting that our current view on the role that TRPM6 plays in regulating the magnesium ion balance in humans may be too simplistic.

To address this question, Chubanov et al. studied mice with mutations that disrupted the production of TRPM6 in specific tissues only. The experiments show that TRPM6 primarily operates in the placenta and intestine to regulate the balance of magnesium ions in the body. Further experiments show that the loss of TRPM6 in adult mice leads to reduced lifespan, growth defects and poor health by disrupting important biochemical reactions. Supplying the mutant mice with magnesium ion supplements improved their health and could extend lifespans of normal animals.

The findings of Chubanov et al. demonstrate that TRPM6 plays a crucial role in regulating the levels of magnesium ions in mice before birth and into adulthood. The next step is to carry out large-scale experiments to investigate the effects of altering the levels of magnesium ions in human diets.

DOI: [10.7554/eLife.20914.002](https://doi.org/10.7554/eLife.20914.002)

a few mutants were found between e11.5–12.5 and no *Trpm6* ^{β_{geo}/β_{geo}} individuals were viable after e14.5 (**Figure 1A**). Compared to e9.5 C-shaped *Trpm6*^{+/+} individuals, all *Trpm6* ^{β_{geo}/β_{geo}} embryos isolated had not turned (S-shaped) and were smaller indicating a developmental retardation after e8.5 (**Figure 1B**). Consequently, we investigated the expression pattern of *Trpm6* in e8.5 fetuses by in situ hybridization (ISH) and found that *Trpm6* was specifically expressed in the visceral yolk sac endoderm and extraembryonic chorion (**Figure 1C**) and that *Trpm6* was not detectable in the neural tube (**Figure 1—figure supplement 1**). Within the placental labyrinth a network of maternal sinusoids are intertwined with fetal blood capillaries, separated by two layers of transporting trophoblast cells, syncytiotrophoblasts I (SynT-I) and II (SynT-II) (**Simmons and Cross, 2005; Simmons et al., 2008**). At e8.5, morphogenesis of the labyrinth is in the initial stages and SynT-I/SynT-II cell layers are distinguishable (**Simmons and Cross, 2005; Simmons et al., 2008**). We observed that *Trpm6* expression was restricted to SynT-I cells (**Figure 1D**). In the fully matured labyrinth at e14.5 *Trpm6* mRNA was detected in syncytiotrophoblasts as well (**Figure 1E**).

Syncytiotrophoblasts and endoderm cells of the yolk sac exchange metabolites between the maternal and fetal blood (**Simmons and Cross, 2005**). To clarify whether TRPM6 is required for Mg²⁺ supply by extraembryonic tissues, we used inductively coupled plasma mass spectrometry (ICP-MS) and found that relative magnesium (Mg²⁺) levels were reduced in the whole e9.5 *Trpm6* ^{β_{geo}/β_{geo}} embryos (**Figure 1F**). Thus, *Trpm6* is specifically expressed in the placental labyrinth and the yolk sac at the stage when the Mg²⁺ deficiency and growth delay of *Trpm6*-deficient embryos become apparent.

To investigate whether TRPM6 activity in extraembryonic cells underlies the lethality of *Trpm6* null embryos, we characterized a mouse strain with a 'floxed' (*Trpm6*^{*fl*}) allele (**Table 1**). Cre-mediated excision engendered viable mice heterozygous for the constitutive deletion mutation in *Trpm6* (*Trpm6* ^{$\Delta 17/+$}). However, we were unable to produce live *Trpm6* ^{$\beta_{geo}/\Delta 17$} or *Trpm6* ^{$\Delta 17/\Delta 17$} offspring, indicating that *Trpm6* ^{$\Delta 17$} is a true null mutation (**Table 1**). The paternally inherited Sox2-Cre transgene drives recombination only in epiblast cells, but not in extraembryonic tissues (**Hayashi et al.,**

Table 1. Postnatal survival of the mice with global and tissue-restricted deletions of *Trpm6*.

Targeted tissue	Breeding strategy	Expected F1 outcome*	Survival of the mutant
Constitutive mutagenesis			
Whole fetus	♂ <i>Trpm6</i> ^{βgeo/+} x ♀ <i>Trpm6</i> ^{βgeo/+}	25% <i>Trpm6</i> ^{βgeo/βgeo} 50% <i>Trpm6</i> ^{βgeo/+} 25% <i>Trpm6</i> ^{+/+}	no
Whole fetus	♂ <i>Trpm6</i> ^{Δ17/+} x ♀ <i>Trpm6</i> ^{Δ17/+}	25% <i>Trpm6</i> ^{Δ17/Δ17} 50% <i>Trpm6</i> ^{Δ17/+} 25% <i>Trpm6</i> ^{+/+}	no
Whole fetus	♂ <i>Trpm6</i> ^{Δ17/+} x ♀ <i>Trpm6</i> ^{βgeo/+}	25% <i>Trpm6</i> ^{βgeo/Δ17} 25% <i>Trpm6</i> ^{βgeo/+} 25% <i>Trpm6</i> ^{Δ17/+} 25% <i>Trpm6</i> ^{+/+}	no
Conditional mutagenesis using Cre/LoxP system			
Epiblast	♂ <i>Trpm6</i> ^{Δ17/+} ;Sox2-Cre x ♀ <i>Trpm6</i> ^{fl/fl}	25% <i>Trpm6</i> ^{Δ17/Δ17} ;Sox2-Cre 25% <i>Trpm6</i> ^{Δ17/fl} 25% <i>Trpm6</i> ^{Δ17/+} ;Sox2-Cre 25% <i>Trpm6</i> ^{fl/+}	yes
Intestine	♂ <i>Trpm6</i> ^{Δ17/+} ;Villin1-Cre x ♀ <i>Trpm6</i> ^{fl/fl}	25% <i>Trpm6</i> ^{Δ17/fl} ;Villin1-Cre [†] 25% <i>Trpm6</i> ^{Δ17/fl} 25% <i>Trpm6</i> ^{fl/+} ;Villin1-Cre 25% <i>Trpm6</i> ^{fl/+}	yes
Kidney	♂ <i>Trpm6</i> ^{Δ17/+} ;Ksp-Cre x ♀ <i>Trpm6</i> ^{fl/fl}	25% <i>Trpm6</i> ^{Δ17/fl} ;Ksp-Cre [†] 25% <i>Trpm6</i> ^{Δ17/fl} 25% <i>Trpm6</i> ^{fl/+} ;Ksp-Cre 25% <i>Trpm6</i> ^{fl/+}	yes

*Genotypes were determined using genomic DNA extracted from tail fragments.

†Individuals were homozygous for *Trpm6*^{Δ17} allele in the targeted cells.

DOI: 10.7554/eLife.20914.005

2003). Notably, intercrosses of *Trpm6*^{Δ17/+};Sox2-Cre males and *Trpm6*^{fl/fl} females resulted in viable *Trpm6*^{Δ17/Δ17} pups at the expected ratio (**Table 1**). Therefore, the embryonic mortality of *Trpm6*-deficient mice appears to be caused by the loss of TRPM6 in extraembryonic tissues.

***Trpm6*-deficient adult mice display shortened lifespan, growth defects and Mg²⁺ deficiency**

We next studied the impact of a global deletion of *Trpm6* postnatally. Examination of *Trpm6*-deficient (*Trpm6*^{Δ17/Δ17};Sox2-Cre) mice at weaning did not reveal conspicuous abnormalities. However, during the follow-up period, we observed the gradual development of pathologies. Thus, *Trpm6*-deficient mice had a lifespan of no longer than 16 weeks (**Figure 2A**). Mutants were growth-delayed, and displayed a lighter fur colour and low night-time activity (**Figure 2B,C**). Weight gain and lean body mass of *Trpm6*-deficient mice were reduced (**Figure 2D,E**), as was the muscle fibre area of the gastrocnemius muscle of 12–13 week-old *Trpm6*-deficient mice indicative of sarcopenia (**Figure 2F**). Mutant mice displayed kyphosis (**Figure 2G**) and completely lacked abdominal and subcutaneous fat depots (**Figure 2H,I**) indicative of catabolic metabolism. However, the total amount of faeces (**Figure 2—figure supplement 1A**) and the calorimetrically determined faecal energy content, as a measure of energy excretion (**Figure 2—figure supplement 1B**), were not altered in *Trpm6* mutants, ruling out insufficient food intake. Histological analysis of internal organs (**Figure 3**) showed that *Trpm6*-deficient mice developed lung emphysema and degeneration of lymphoid organs. Thus, the thymus of mutant mice was rudimentary and the cortex region was not distinguishable. In the spleen of *Trpm6*-deficient mice, the red pulp was substantially reduced. Hepatocytes of *Trpm6*-deficient mice were depleted of glycogen granules (**Figure 3**), corroborating catabolic metabolism. It has been suggested that low serum Mg²⁺ and TRPM6 function are associated with atherosclerosis in humans (**Maier, 2012; Tin et al., 2015**). Therefore, we investigated whether such a phenotype would develop in our mouse model as well. However, examination of thoracic aorta showed no signs of atherosclerosis development in mutant mice (**Figure 2—figure supplement 2**).




Figure 1. Assessment of *Trpm6* function in extraembryonic tissues. (A) Survival of *Trpm6* ^{β geo/ β geo} embryos obtained from *Trpm6* ^{β geo/+} intercrosses. (B) Representative images of e9.5 *Trpm6*^{+/+} (+/+, n = 13) and *Trpm6* ^{β geo/ β geo} (β geo/ β geo, n = 5) embryos from dataset in (A). Dashed lines underline C-shaped versus S-shaped morphology of *Trpm6*^{+/+} and *Trpm6* ^{β geo/ β geo} embryos, respectively. (C) ISH on serial paraffin sections obtained from wildtype n = 5 e8.5 fetus using antisense (left) and sense (right) probes for *Trpm6*. Boxes indicate the positions of the magnified images of the chorion

Figure 1 continued on next page

Figure 1 continued

(ch) and yolk sac (yc). Arrows indicate *Trpm6*-positive cells in the developing labyrinth (chorion) and the endoderm layer in the visceral yolk sac. (D) ISH on serial paraffin sections of wildtype e8.5 placenta using DIG-labelled probes for *Trpm6* (left), *SynA* (middle) and *Gcm1* (right), respectively. Note: *Trpm6* expression was restricted to cells positive for *SynA*, a marker of SynT-I, and absent in cells expressing *Gcm1*, a marker of SynT-II. Representative images of $n = 2$ independent tissues are shown. (E) ISH of WT e14.5 placenta with the antisense *Trpm6* probe. The box indicates the position of the magnified image. The *Trpm6* signal is restricted to the labyrinth (lab) and not detectable in the decidua (dec) and trophoblast giant cells (GT). Representative images of $n = 8$ independent placentas are shown. (F) Mg^{2+} levels in e9.5 *Trpm6*^{+/+} ($n = 4$) and *Trpm6* ^{β geo/ β geo} ($n = 3$) embryos. Distal segments of the embryos were used for genotyping, and the remaining parts were analysed by ICP-MS. Elementary magnesium (Mg) contents were normalized to phosphorus (P) and sulfur (S) levels represented as mean \pm SEM. *- $p \leq 0.05$ (Student's t-test).

DOI: 10.7554/eLife.20914.003

The following figure supplement is available for figure 1:

Figure supplement 1. ISH on serial paraffin sections obtained from wildtype e8.5 fetus using antisense (left) and sense (right) probes for *Trpm6*.

DOI: 10.7554/eLife.20914.004

Next, we asked whether the phenotype of *Trpm6*-deficient mice is caused by Mg^{2+} deficiency. We employed ICP-MS to compare the concentrations of main elements in serum from controls and *Trpm6*-deficient littermates. We found that, similar to humans with mutations in the *TRPM6* gene (Schlingmann et al., 2002; Walder et al., 2002), *Trpm6*-deficient mice developed hypomagnesemia (Figure 2J). Serum Mg^{2+} levels of mutant mice were only 0.58 mM (36% of control value, 1.58 mM), whereas concentrations of other elements were not changed (Figure 2J). A Mg^{2+} -enriched diet is an efficient way to alleviate hypomagnesemia in humans lacking TRPM6 (Schlingmann et al., 2002; Walder et al., 2002). Therefore, we asked whether the phenotypes of *Trpm6*-deficient mice were caused by Mg^{2+} deprivation and could be rescued by dietary supplementation. To this end, we changed the regular chow (0.22% Mg^{2+}) of 4 week-old mutant mice and control littermates for a Mg^{2+} enriched diet (0.75% Mg^{2+}). Notably, none of the *Trpm6*-deficient mice died during the following 12 weeks of Mg^{2+} supplementation (Figure 2K). However, returning to regular chow resulted in 100% mortality of mutant mice within the following 13 weeks (Figure 2K). Mg^{2+} supplemented mutants neither exhibited kyphosis nor lipodystrophy (data not shown). Furthermore, the morphology of the lung, spleen, and thymus of Mg^{2+} supplemented mutants closely resembled that of control mice (Figure 3). We asked whether dietary Mg^{2+} supplementation of *Trpm6* ^{β geo/+} parents would benefit the survival of *Trpm6*-deficient offspring. However, similar to a previous study (Walder et al., 2009), we found that this treatment was inefficient.

Trpm6-deficient adult mice phenocopy salient pathologies reported for a set of mouse strains advocated as genetic models of 'accelerated' or 'premature' aging (Kuro-o et al., 1997; Trifunovic et al., 2004; Kujoth et al., 2005; Varela et al., 2005; Mostoslavsky et al., 2006; Niedernhofer et al., 2006; van der Pluijm et al., 2007; López-Otín et al., 2013). Similar to *Trpm6*-deficient mice, the latter mutants display short lifespan, growth failure, low physical activity, kyphosis, lung emphysema, sarcopenia, lipodystrophy and degeneration of lymphoid organs. A characteristic feature of these mouse strains is suppression of the somatotrophic axis accompanied by induction of xenobiotic detoxification gene networks in the liver (Niedernhofer et al., 2006; van de Ven et al., 2006; van der Pluijm et al., 2007; Schumacher et al., 2008; Garinis et al., 2009; Mariño et al., 2010), interpreted as a defensive organismal response, slowing down growth and metabolism in favor of somatic preservation (López-Otín et al., 2013). We asked whether *Trpm6*-deficient mice would also display such protective metabolic responses. In fact, we found that serum IGF1 concentrations were reduced in *Trpm6*-deficient mice as well (Figure 4A). Mutant mice had a lower core body temperature (Figure 4B) and a profoundly reduced urinary content of major urinary proteins (MUPs) (Figure 4C), two known features of suppressed IGF1 signalling (Mariño et al., 2010; Bartke et al., 2013). Even though mutant mice showed signs of overall energy shortage, circulating levels of ketone bodies (β -hydroxybutyrate) were not elevated (Figure 2—figure supplement 1C). When subjected to an oral glucose tolerance test, mutant mice displayed lower peripheral glucose concentrations than controls despite of a similar amount of insulin released, thus reflecting increased insulin sensitivity (Figure 2—figure supplement 1D,E), another hallmark of suppressed IGF1 signalling (Bartke et al., 2013). Notably, body weight and IGF1 serum levels were indistinguishable in Mg^{2+} supplemented mutant and control mice suggesting that the variations observed in mice maintained on a regular diet were induced by Mg^{2+} deficiency (Figure 2—figure supplement 1F,G).




Figure 2. Pathophysiological changes displayed by *Trpm6*-deficient adult mice. Unless stated otherwise, 10–12 week-old *Trpm6*^{fl/+} (Control) and *Trpm6* ^{$\Delta^{17/\Delta^{17}}$;Sox2-Cre} (KO) littermates were studied. (A–E) Mice were examined for survival rate (A), overall physical appearance (B), day/night activity of 8 week-old individuals (C), growth rate (D) and lean mass (E). (F) Fibre size of the gastrocnemius muscle after hematoxylin-eosin staining. (G) X-ray images of mice. The red arrow indicates the characteristic skeletal deformation (kyphosis) observed in *Trpm6*-deficient mice. (H) Assessment of muscle morphology. (I) Histological sections of skeletal muscle. (J) Serum electrolyte levels. (K) Survival rate on different Mg²⁺ diets. Figure 2 continued on next page

Figure 2 continued

abdominal fat. Arrows indicate fat deposits observed only in control mice. (I) H and E staining of paraffin skin sections. Arrows indicate a layer of fat cells present only in control mice. Histological analysis was performed with three animals per group resulting in similar observations. (J) The levels of main elements in the serum of 8 week-old mice assessed by ICP-MS. (K) The survival rate of mice maintained on high Mg^{2+} (0.75%) and regular (0.22%) chows. Data are represented as mean \pm SEM. ***- $p\leq 0.001$; **- $p\leq 0.01$; *- $p\leq 0.05$; n.s. – not significantly different (Student's t-test); n – number of mice examined.

DOI: [10.7554/eLife.20914.006](https://doi.org/10.7554/eLife.20914.006)

The following figure supplements are available for figure 2:

Figure supplement 1. Examination of energy balance in *Trpm6*-deficient mice.

DOI: [10.7554/eLife.20914.007](https://doi.org/10.7554/eLife.20914.007)

Figure supplement 2. Evaluation of atherosclerosis development in *Trpm6*-deficient mice.

DOI: [10.7554/eLife.20914.008](https://doi.org/10.7554/eLife.20914.008)




Figure 3. Histology of internal organs of *Trpm6*-deficient mice. Hematoxylin-eosin staining of paraffin embedded tissue sections of 12–13 week-old control (*Control*) and *Trpm6*-deficient (*KO*) mice maintained either on regular (0.22% Mg^{2+}) or Mg^{2+} supplemented (0.75% Mg^{2+}) chows. *Trpm6*-deficient mice maintained on the regular diet showed marked airspace enlargement (indicated by stars) mimicking lung emphysema, distortion of splenic red pulp (*rp*)/ white pulp (*wp*) microarchitecture, thymic atrophy, and reduction of intracellular glycogen in hepatocytes (indicated by arrows). Histological analysis was performed with three animals per group resulting in similar observations.

DOI: [10.7554/eLife.20914.009](https://doi.org/10.7554/eLife.20914.009)




Figure 4. Assessment of metabolic profiles of *Trpm6*-deficient mice. (A–C) 8 week-old *Trpm6*^{fl/+} (Control) and *Trpm6*^{Δ17/Δ17};Sox2-Cre (KO) littermates were evaluated for (A) serum IGF1, (B) body temperature, (C) urinary MUPs content in individual mice. Data are represented as mean±SEM. ***-p≤0.001; *-p≤0.05 (Student's t-test); n – number of mice examined. (D) IPA analysis of genome-wide hepatic transcriptome profiling of *Trpm6*-deficient (n = 3) vs control (n = 4) littermates. The diagram shows the top 5 of IPA Canonical Pathways significantly changed in mutant mice (**Supplementary file Figure 4 continued on next page**)

Figure 4 continued

2). Numbers of the commonly changed transcripts are indicated close to the lines connecting the pathways. (E) Venn diagram for sets of metabolites significantly changed (FDR $p \leq 0.05$) in serum, liver and gastrocnemius muscle *Trpm6*-deficient ($n = 6$) vs control ($n = 8$) littermates (**Supplementary file 3**). Commonly changed metabolites are listed in different colours as outlined in the Venn diagram. (F–J) Levels of AC C18:1 (F–H) and AC C18 (I–J) examined in the serum (F, I), liver (G) and gastrocnemius muscle (H, J) of *Trpm6*-deficient and control mice. Data are represented as mean \pm SEM. ***- $p \leq 0.001$; **- $p \leq 0.01$; *- $p \leq 0.05$; n.s. – not significantly different to control group maintained on a regular Mg^{2+} diet (one-way ANOVA); n – number of mice examined. (K) ATP production by mitochondria isolated from the liver of wildtype C57BL/6 mice with succinate, palmitoylcarnitine or octanoylcarnitine as energy sources. ATP levels were determined after 30 min incubation of untreated (-) or treated (+) mitochondria by EDTA with or without Mg^{2+} . Data are represented as mean \pm SEM of 4–5 independent isolations (N). ##- $p \leq 0.01$; #- $p \leq 0.05$ significantly different to the control group; ***- $p \leq 0.001$; **- $p \leq 0.01$; *- $p \leq 0.05$ significantly different to the EDTA treated group (Student's t-test). n.s. – not significantly different.

DOI: [10.7554/eLife.20914.010](https://doi.org/10.7554/eLife.20914.010)

The following figure supplements are available for figure 4:

Figure supplement 1. Gene expression profiling of *Trpm6*-deficient and control mice.

DOI: [10.7554/eLife.20914.011](https://doi.org/10.7554/eLife.20914.011)

Figure supplement 2. Metabolomic profiling of *Trpm6*-deficient and control mice.

DOI: [10.7554/eLife.20914.012](https://doi.org/10.7554/eLife.20914.012)

Figure supplement 3. Assessment of the membrane potential ($\Delta\Psi_m$) in isolated mitochondria.

DOI: [10.7554/eLife.20914.013](https://doi.org/10.7554/eLife.20914.013)

Finally, we performed whole-genome profiling of the liver transcriptome (**Supplementary file 1**). Applying a cut-off value of $p \leq 0.1$ for the false discovery rate (FDR), we identified 46 genes up- or down-regulated in the livers of *Trpm6*-deficient mice (**Figure 4—figure supplement 1**, **Supplementary file 1**). The majority of affected transcripts code for solute carrier transporters, cytochrome P450 metabolising enzymes, glutathione S-transferases and proteins metabolizing steroids. As expected, Ingenuity Pathway Analysis (IPA) revealed that the inactivation of *Trpm6* is associated with an induction of interconnected gene networks controlling toxicity responses and xenobiotic metabolism governed by nuclear receptors such as retinoid X receptors (RXR), liver X receptor (LXR) and farnesoid X receptor (FXR) (**Figure 4D**, **Supplementary file 2**). Hence, *Trpm6*-deficient mice were characterized by suppression of the somatotrophic axis and induction of xenobiotic detoxification responses.

***Trpm6*-deficient mice display insufficient utilization of long-chain acylcarnitines**

To gain mechanistic insight into the altered energy metabolism of mutant mice, we quantified serum, liver and skeletal muscle levels of 237 metabolites (**Supplementary file 3**, **Figure 4—figure supplement 2**). Unexpectedly, alterations in *Trpm6*-deficient mice (FDR $p \leq 0.1$) were restricted to only several metabolites representing mainly long-chain acylcarnitines (AC), phosphatidylcholines (PC), and sphingomyelins (SM) (**Figure 4E**). These findings, as well as the results of gene array profiling (**Figure 4D**) suggest that sustained Mg^{2+} deficiency triggers a specific metabolic response rather than widespread unsystematic changes. In line with this idea, we noted that AC C18:1 and the related AC C18 were consistently increased in tissues of *Trpm6*-deficient mice (**Figure 4F–J**), whereas carnitine levels were not changed (**Supplementary file 3**). In conjunction with lowered concentrations of glucose and unchanged ketogenesis (**Figure 2—figure supplement 1C**), this constellation is a metabolic 'signature' of a frequent inherited human disorder characterized by inefficient β -oxidation of fatty acids due to mitochondrial carnitine palmitoyltransferase II deficiency (**Gempel et al., 2002; Bonnefont et al., 2004**). AC C18:1 and C18 levels were normalized in serum and tissues obtained from Mg^{2+} supplemented mutants (**Figure 4F–J**), implying that metabolic changes of AC were caused by Mg^{2+} deficiency.

Consequently, we asked whether Mg^{2+} would specifically affect mitochondrial ATP production (**Figure 4K**) and maintenance of the mitochondrial membrane potential (MMP) (**Figure 4—figure supplement 3A**). To address this question, wildtype liver mitochondria were incubated in a buffer containing 3 mM EDTA with or without 1–5 mM Mg^{2+} . Such manipulations had no negative effect on mitochondrial respiration when succinate was offered as an energy source (**Figure 4K**, **Figure 4—figure supplement 3A**). In contrast, mitochondria failed to utilize octanoylcarnitine or palmitoylcarnitine for ATP production (**Figure 4K**) and to maintain MMP (**Figure 4—figure supplement 3A**) in the

presence of EDTA. Importantly, ATP production and MMP could be fully rescued by the administration of 3–5 mM Mg^{2+} (**Figure 4K**, **Figure 4—figure supplement 3A**), but not Zn^{2+} or Ca^{2+} (**Figure 4—figure supplement 3B**). Thus, sustained Mg^{2+} deprivation impairs energy homeostasis resulting in a catabolic metabolism in *Trpm6*-deficient mice, at least partially due to insufficient mitochondrial utilization of AC.

***Trpm6* null mice develop Mg^{2+} deficiency due to a defect in intestinal Mg^{2+} uptake**

Next, we investigated the etiology of hypomagnesemia in *Trpm6*-deficient mice. ~50% of body Mg^{2+} content is stored in bones, ~30% in muscle tissues and only ~1% in the serum (*de Baaij et al., 2015*). Using ICP-MS we studied the Mg^{2+} content in bones (right tibia) and gastrocnemius muscle, and observed that Mg^{2+} levels in bones of *Trpm6* null mice were only 24% of control values (**Figure 5A**). Furthermore, the Mg^{2+} content of muscle was also significantly reduced in *Trpm6*-deficient mice (**Figure 5B**). Hence, *Trpm6*-deficient mice develop a severe systemic Mg^{2+} deficit.

It is generally assumed that the distal convoluted tubule (DCT) of the kidney is critical for whole-body Mg^{2+} balance (*de Baaij et al., 2015*). Accordingly, immunostaining of control kidney cryosections with a TRPM6-specific antibody labelled nephron segments resembling DCT (**Figure 5C**). TRPM6 was not detectable in the kidneys of *Trpm6*-deficient mice. Surprisingly, mutant mice exhibited substantially reduced urinary Mg^{2+} excretion (only 14% of control values, **Figure 5D**), whereas fecal Mg^{2+} loss was significantly increased (166%, **Figure 5E**), indicating that mice lacking TRPM6 develop Mg^{2+} deficiency primarily due to impaired intestinal Mg^{2+} uptake. Therefore, we studied the expression pattern of *Trpm6* in the intestine. Because the TRPM6-specific antibody did not efficiently and specifically detect TRPM6 protein in the intestine, we resorted to ISH (**Figure 5—figure supplement 1**). *Trpm6* transcripts were not detectable in the small intestine, but *Trpm6*-specific signal was observed in absorptive epithelial cells of the colon (**Figure 5—figure supplement 1**). The colon of mutant mice was not stained by a *Trpm6*-specific ISH probe (**Figure 5F**), consistent with the notion that systemic Mg^{2+} deficit in *Trpm6*-deficient mice was primarily caused by a defect of Mg^{2+} uptake in the colon.

To directly assess the contribution of the kidney versus intestine to the *Trpm6* null phenotype, we employed *Ksp-Cre* (*Shao et al., 2002*) and *Villin1-Cre* (*Madison et al., 2002*) transgenic mice to specifically ablate floxed *Trpm6* alleles in renal and intestinal epithelial cells, respectively (**Table 1**). Surprisingly, conditional *Trpm6* inactivation in the kidney neither impacted serum Mg^{2+} concentration nor urinary Mg^{2+} excretion, and bone Mg^{2+} content was only slightly reduced (**Figure 5G–J**). In contrast, disruption of *Trpm6* in the intestine resulted in hypomagnesemia, reduced bone Mg^{2+} content and lowered urinary Mg^{2+} excretion (**Figure 5K–N**), indicating that wildtype kidneys are not able to compensate for the ablation of intestinal TRPM6. Hence, in contrast to current thinking, our findings support the new concept that *Trpm6*-dependent Mg^{2+} uptake in the intestine plays an indispensable role for systemic Mg^{2+} balance.

TRPM6 cooperates with TRPM7 to regulate divalent cation currents

TRPM6 is invariably co-expressed with the TRPM7 channel and the question as to why TRPM6 function is non-redundant remains central to a mechanistic understanding of the *Trpm6* null phenotype. Because *Trpm6* expression levels in the epithelial cells of the colon (**Figure 5—figure supplement 1**) and the kidney (**Figure 5C**) are highly heterogeneous, we searched for an alternative native cell model to dissect the functional interplay of TRPM6 and TRPM7. Trophoblast stem (TS) cells are widely used to study the transport function of placental trophoblasts (*Tanaka et al., 1998*; *Simmons and Cross, 2005*) and, as shown before (**Figure 1**), this cell type is crucial for the fetal *Trpm6* phenotype. Therefore, we derived *Trpm6*^{+/+} and *Trpm6*-deficient (*Trpm6*^{βgeo/βgeo}) TS cells from e3.5 blastocysts isolated from *Trpm6*^{βgeo/+} parents (**Figure 6—figure supplement 1A**). We also produced *Trpm7*^{+/+} and *Trpm7*-deficient (*Trpm7*^{Δ17/Δ17}) TS cells (**Figure 6—figure supplement 2A**) using *Trpm7*^{Δ17/+} mice (*Jin et al., 2008*). As expected, RT-PCR analysis revealed that wildtype TS cells expressed TRPM6 and TRPM7 (**Figure 6—figure supplement 1B**, **Figure 6—figure supplement 2B**). *Trpm6*^{βgeo/βgeo} TS cells were maintained in culture for >40 passages. Furthermore, analysis of DNA content showed that the proportion of polyploidy was similar in *Trpm6*^{+/+} and *Trpm6*^{βgeo/βgeo} TS cells (**Figure 6—figure supplement 1C,D**), suggesting that inactivation of *Trpm6*




Figure 5. Examining of Mg^{2+} balance in *Trpm6*-deficient adult mice. (A–F) Assessment of 8 week-old *Trpm6*^{fl/+} (Control) and *Trpm6* ^{$\Delta 17/\Delta 17$} ;Sox2-Cre (KO) littermate males. (A) Mg^{2+} levels in bones and (B) gastrocnemius muscle assessed by ICP-MS. (C) Immunostaining of kidney cryosections using a TRPM6-specific antibody. Representative images are shown (n = 2 tissues per genotype). The blue square indicates the position of the confocal and differential interference contrast magnified images acquired from control tissue. Arrows indicate labelling of the apical surface of renal tubules. (D) 24 hr

Figure 5 continued on next page

Figure 5 continued

urinary and (E) fecal Mg^{2+} excretion rates. (F) ISH on paraffin sections obtained from the colon of control and *Trpm6*-deficient mice ($n = 2$ tissues per genotype). (G–J) Examination of 6 month-old *Trpm6*^{fl/+} (Control) and *Trpm6* ^{$\Delta 17/fl$} ;Ksp-Cre (Kidney KO) littermate males. (G) Immunostaining of TRPM6 in kidney cryosections. Arrows indicate labelling of renal tubules. (H–I) Determination of Mg^{2+} in serum (H) and bones (I). (J) 24 hr urinary Mg^{2+} excretion rate. (K–N) Assessment of 6 month-old *Trpm6*^{fl/+} (Control) and *Trpm6* ^{$\Delta 17/fl$} ;Villin1-Cre (Intestine KO) littermate males. (K) ISH on paraffin sections of the colon using a *Trpm6*-specific probe ($n = 2$ tissues per genotype). (L, M) Mg^{2+} levels in the serum (L) and bones (M). (N) 24 hr urinary Mg^{2+} excretion rate. Data are represented as mean \pm SEM. ***- $p \leq 0.001$; **- $p \leq 0.01$; *- $p \leq 0.05$; n.s. – not significantly different (Student's t-test); n – number of mice examined. Histological analysis in (F) and (K) was performed with $n = 3$ animals per group resulting in similar observations.

DOI: 10.7554/eLife.20914.014

The following figure supplement is available for figure 5:

Figure supplement 1. Expression pattern of *Trpm6* in the intestine.

DOI: 10.7554/eLife.20914.015

did not affect the self-renewal of *Trpm6* ^{$\beta geo/\beta geo$} stem cells. In contrast, *Trpm7* ^{$\Delta 17/\Delta 17$} TS cells did not proliferate, unless the cell culture medium was supplemented with additional Mg^{2+} (Figure 6—figure supplement 2C), supporting the concept that TRPM7 plays a pivotal role in cellular Mg^{2+} uptake that cannot be maintained by TRPM6 alone (Schmitz et al., 2003; Chubanov et al., 2004; Ryazanova et al., 2010).

TRPM6 and TRPM7 have been suggested as molecular correlates of $MgATP$ - and Mg^{2+} -regulated cation currents responsible for the cellular uptake of divalent cations including Mg^{2+} (Aarts et al., 2003; Nadler et al., 2001; Schmitz et al., 2003; Chubanov et al., 2004; Voets et al., 2004; Zhang et al., 2014). Patch-clamp analysis showed that *Trpm6* ^{$\beta geo/\beta geo$} TS cells display substantially reduced TRPM6/M7-like outward currents at +80 mV (Figure 6A). Due to permeation block by extracellular divalent cations (Nadler et al., 2001; Fleig and Chubanov, 2014), inward currents at physiological membrane potentials were very small (Figure 6A; $p \leq 0.001$, t-test). However, exposure of TS cells to a divalent cation free (DVF) solution resulted in large monovalent cation currents (Figure 6B). Under these conditions, mutant TS cells exhibited a comparable reduction of inward ($p \leq 0.01$, t-test) as well as outward ($p \leq 0.05$, t-test) monovalent currents (Figure 6B).

Cytosolic levels of free Mg^{2+} ($[Mg^{2+}]_i$) and $MgATP$ ($[MgATP]_i$) have been suggested to exert a negative feedback mechanism on TRPM6/M7 channel activity (Fleig and Chubanov, 2014). We observed (Figure 6C) that currents in *Trpm6* ^{$\beta geo/\beta geo$} TS cells were more susceptible to concentration-dependent inhibition by cytosolic $MgATP$ ($p \leq 0.0001$, F-test). The calculated IC_{50} value for *Trpm6*^{+/+} was 3.17 mM (Hill (h) slope = -1.81). Currents in *Trpm6* ^{$\beta geo/\beta geo$} cells were inhibited by $[MgATP]_i$ with an IC_{50} value of 1.45 mM ($h = -1.95$; $p \leq 0.0015$, F-test). These results suggest that physiological concentrations of $[MgATP]_i$ varying between 2–7 mM in mammalian cells (Günther, 2006; Romani, 2011) will affect currents in *Trpm6*^{+/+} and *Trpm6* ^{$\beta geo/\beta geo$} cells differently. In contrast, we observed no significant differences in $[Mg^{2+}]_i$ concentration-response curves for *Trpm6*^{+/+} and *Trpm6* ^{$\beta geo/\beta geo$} currents ($p = 0.62$, F-test) (Figure 6D). The obtained IC_{50} value for *Trpm6*^{+/+} currents was 0.60 mM ($h = -1.14$) and was not significantly altered in *Trpm6* ^{$\beta geo/\beta geo$} TS cells (0.72 mM, $h = -1.18$; $p = 0.22$, F-test), suggesting that physiological concentrations (0.3–1 mM, (Günther, 2006; Romani, 2011)) of $[Mg^{2+}]_i$ will exert similar effects on ion currents in *Trpm6*^{+/+} and *Trpm6* ^{$\beta geo/\beta geo$} cells.

Next, we asked whether TRPM6 channel activity would be detectable in the absence of TRPM7. Remarkably, we observed that *Trpm7* ^{$\Delta 17/\Delta 17$} TS cells completely lacked TRPM6/M7-like currents (Figure 6E,F). These findings cogently support our model (Chubanov et al., 2004) that native TRPM6 primarily functions in close cooperation with TRPM7. TRPM6 facilitates Mg^{2+} uptake by increasing the amplitude of TRPM7-like currents and relieving TRPM7 from the negative feedback by $MgATP$ (Figure 6G).

Finally, we studied whether Mg^{2+} deprivation may affect energy metabolism at the cellular level. We chose the genetically tractable human haploid leukaemia cell line (HAP1 cells) (Essletzbichler et al., 2014; Blomen et al., 2015; Wang et al., 2015) as a new model system. CRISPR/Cas9-mediated ablation of the TRPM7 protein in HAP1 cells (Figure 6—figure supplement 3A,B) completely abolished TRPM7-like currents (Figure 6—figure supplement 3C). When cultured in standard medium for 24 hr, TRPM7-deficient cells were characterized by a reduced total cellular Mg^{2+} content and a Mg^{2+} -dependent proliferation defect (Figure 6—figure supplement 3D,E). In




Figure 6. Characterization of TRPM6/M7-like currents in *Trpm6*- and *Trpm7*-deficient TS cells. (A) *Left panel:* Whole-cell currents measured at -80 mV and $+80$ mV over time in *Trpm6*^{+/+} ($n = 22$) and *Trpm6* ^{$\beta geo/\beta geo$} ($n = 22$) TS cells. *Middle panel:* Representative current-voltage relationships obtained at 12 s and 400 s. *Right panel:* Bar graphs of current amplitudes at $+80$ mV (400 s). (B) Measurements were performed in control ($n = 16$) and *Trpm6*-deficient ($n = 14$) TS cells analogous to (A) except that the external saline (containing 2 mM Mg^{2+} and 1 mM Ca^{2+}) was exchanged with divalent-free saline. (C) Currents were measured in control ($n = 16$) and *Trpm6*-deficient ($n = 14$) TS cells analogous to (A) except that the external saline (containing 2 mM Mg^{2+} and 1 mM Ca^{2+}) was exchanged with divalent-free saline. (D) Currents were measured in control ($n = 16$) and *Trpm6*-deficient ($n = 14$) TS cells analogous to (A) except that the external saline (containing 2 mM Mg^{2+} and 1 mM Ca^{2+}) was exchanged with divalent-free saline. (E) Currents were measured in control ($n = 16$) and *Trpm7* ^{$\Delta 17/\Delta 17$} ($n = 14$) TS cells analogous to (A) except that the external saline (containing 2 mM Mg^{2+} and 1 mM Ca^{2+}) was exchanged with divalent-free saline. (F) Current-voltage relationships obtained at 300 s in control ($n = 16$) and *Trpm7* ^{$\Delta 17/\Delta 17$} ($n = 14$) TS cells analogous to (A) except that the external saline (containing 2 mM Mg^{2+} and 1 mM Ca^{2+}) was exchanged with divalent-free saline. (G) Schematic of the TRPM6/7 channel complex. TRPM6 and TRPM7 are shown. Mg^{2+} enters through TRPM6 and TRPM7. $MgATP$ is shown as an inhibitor of TRPM7.

Figure 6 continued

(DVF) solution (black bar). *Right panel* shows currents measured before (filled bars) and after application of DVF solution (open bars) at 400 s and 600 s, respectively. (C, D) Dose-dependent inhibition of currents (+80 mV, 400 s) by [MgATP]_i and [Mg²⁺]_i, respectively (n = 4–18 cells per concentration). (E, F) Whole-cell currents of *Trpm7*^{+/+} (n = 15) and *Trpm7*^{Δ17/Δ17} (n = 10) TS cells studied similar to (A, B). Data are represented as mean±SEM. ***-p≤0.001; **-p≤0.01; *-p≤0.05; n.s. – not significantly different (Student's t-test). n – number of cells examined. (G) A suggested model for the molecular role of TRPM6 in epithelial cells.

DOI: 10.7554/eLife.20914.016

The following figure supplements are available for figure 6:

Figure supplement 1. Characterization of *Trpm6*-deficient TS cells.

DOI: 10.7554/eLife.20914.017

Figure supplement 2. Examination of TS cells deficient in *Trpm7*.

DOI: 10.7554/eLife.20914.018

Figure supplement 3. Evaluation of human haploid leukaemia (HAP1) cells deficient in *TRPM7*.

DOI: 10.7554/eLife.20914.019

addition, *TRPM7*-deficient HAP1 cells had reduced intracellular ATP levels (**Figure 6—figure supplement 3F**). Finally, the respiration rate of *TRPM7*-deficient HAP1 cells was significantly lower when compared to control cells (**Figure 6—figure supplement 3G,H**).

Assessment of dietary Mg²⁺ fortification on the lifespan of wildtype mice

Our studies with *Trpm6*-deficient mice clearly demonstrated that a sustained disruption of Mg²⁺ homeostasis is detrimental for overall health and eventually reduces the lifespan of affected animals. Conversely, we asked whether a Mg²⁺-enriched diet might exert a beneficial effect on the lifespan of wildtype mice. Since there are no prior reports on lifespan extension of mice subjected to life-long dietary Mg²⁺ supplementation (or any other mineral), we performed proof-of-principle experiments to investigate, if such an effect can be observed. To this end, we used only the long-lived B6C3F1 hybrid mouse strain to avoid genotype-specific effects on disease susceptibility observed in longevity experiments with inbred strains (*Lipman et al., 1999; Turturro et al., 1999; Mitchell et al., 2016*). At this stage, we studied only females because of a larger number of early losses of males due to fighting (*Miller et al., 2007*). Finally, we studied animals only under pathogen-free conditions, since Mg²⁺ may elicit a protective effect via the immune system (*Brandao et al., 2013; Chaigne-Delalande et al., 2013*). Consistent with published reports (*Turturro et al., 1999*), the mean lifespan of B6C3F1 mice (886 days regarded as 100%) was significantly extended (1100 days, 125%) by dietary restriction (DR) (**Figure 7A,B, Table 2**). Remarkably, supplementation with three Mg²⁺ salts (Mg(CH₃COO)₂, Mg(OH)₂ and MgCl₂) increased the mean lifespan of mice by approximately 10% (976, 976 and 961 days, respectively). The nutritional CaCl₂ administration was without any significant effect (828 days). In contrast to DR, animals supplemented with Mg²⁺ had a normal or even increased body weight (**Figure 7C**), ruling out the possibility that high dietary Mg²⁺ affected the lifespan of mice due to reduced food intake. Hence, opposite to *Trpm6*-dependent Mg²⁺ deprivation, dietary Mg²⁺ supplementation may have a beneficial effect on the lifespan of mice suggestive future large-scale longevity studies with varied conditions and species.

Discussion

Here, we present a new mechanistic model of the regulation of Mg²⁺ homeostasis during development and postnatal life of mice. Against current thinking we show *in vivo* that TRPM6 is not required for embryonic development per se, but primarily operates in placenta and intestine to regulate Mg²⁺ levels by transcellular transport, while TRPM6 function in the kidney – commonly thought to be essential – is expendable for organismal Mg²⁺ balance. We demonstrate that ablation of TRPM6 in adult mice leads to reduced lifespan, growth defects and profoundly impaired health of mutant mice due to defective energy metabolism. We also show that dietary Mg²⁺ supplementation is not only sufficient to prevent all *Trpm6* null pathologies, but Mg²⁺ is the only mineral known so far able to extend the lifespan of wildtype mice.




Figure 7. Effects of whole-life Mg^{2+} dietary treatments on B6C3F1 mouse strain. (A) Mean survival ages of B6C3F1 mice maintained at a control diet (Control, $n = 335$), under dietary restriction (DR, $n = 60$), or supplemented by $Mg(CH_3COO)_2$ (MgAc, $n = 15$), $Mg(OH)_2$ ($n = 15$), $MgCl_2$ ($n = 15$) and $CaCl_2$ ($n = 15$) in drinking water as outlined in **Table 2**. Pooled Mg shows results for all Mg^{2+} supplemented mice pooled within a common group ($n = 45$). The obtained survival distributions were analysed by the MATLAB computing environment to calculate mean lifespans and corresponding P-values: ***- $p \leq 0.001$; **- $p \leq 0.01$; *- $p \leq 0.05$; n.s. – not significantly different. Alternatively, survival data of control mice versus individually treated groups were assessed by log-rank test: ###- $p \leq 0.001$; ##- $p \leq 0.01$; #- $p \leq 0.05$; n.s. – not significantly different. (B) Kaplan-Meier survival distributions of B6C3F1 mice maintained on control diet (Control), Mg^{2+} supplemented groups (MgAc, $MgCl_2$, $Mg(OH)_2$) or mice under dietary restriction (DR). (C) Body weights (mean \pm SEM) of control and nutritionally fortified mice studied in (A). ***- $p \leq 0.001$; **- $p \leq 0.01$; *- $p \leq 0.05$; n.s. – not significantly different (one-way ANOVA). n – number of mice examined.

DOI: [10.7554/eLife.20914.020](https://doi.org/10.7554/eLife.20914.020)

Table 2. Dietary regimes used to maintain B6C3F1 mice.

Experimental group	Chow 5 K54	Drinking water (ad libitum)	Number of mice
Control	ad libitum	Regular water*	335
Dietary restriction	60% of ad libitum	Regular water	60
Magnesium acetate supplemented	ad libitum	1 g/l Mg(CH ₃ COO) ₂ ·(H ₂ O) ₄ in regular water	15
Magnesium chloride supplemented	ad libitum	1 g/l MgCl ₂ in regular water	15
Magnesium hydroxide supplemented	ad libitum	14 mg/l Mg(OH) ₂ in regular water [†]	15
Calcium chloride supplemented	ad libitum	0.8 g/l CaCl ₂ in regular water	15

*Regular water contained 0.44 mg/l Mg²⁺.

[†]Mg(OH)₂ concentration was lowered to prevent overall alkalization of the diet.

DOI: [10.7554/eLife.20914.021](https://doi.org/10.7554/eLife.20914.021)

It has been reported that constitutive *Trpm6* inactivation leads to embryonic lethality, resulting in the generally accepted tenet that *Trpm6* is required for the development of the embryo proper (Walder et al., 2009). On the contrary, we provide genetic evidence that the embryonic mortality of *Trpm6*-deficient mice is caused by the loss of TRPM6 activity in placental SynT-I and yolk sac endoderm cells, and that *Trpm6*-deficient embryos are depleted of Mg²⁺. Altogether, we postulate that *Trpm6* controls the maternal Mg²⁺ supply to the fetus, and that growth failure and death are secondary phenotypes induced by Mg²⁺ deprivation. Differences in the role of TRPM6 for embryonic survival of humans and mice may be attributable to different morphologies of the placental exchange interfaces, fetal growth rate, litter size and dietary preferences (Simmons and Cross, 2005). However, at present we cannot exclude that loss-of-function mutations in *TRPM6* might be associated with prenatal mortality in humans as well. Pioneering positional cloning studies (Schlingmann et al., 2002; Walder et al., 2002) and follow-up case reports (Schlingmann et al., 2005; Konrad and Schlingmann, 2014) focused on hospitalized human infants selected by the criterion of deleterious Mg²⁺ deficiency. Hence, additional *TRPM6* phenotypes, such as infertility or embryonic death, might have been overlooked. Accordingly, it has recently been shown that single nucleotide polymorphisms in human *TRPM6* are associated with a neural tube closure defect, i.e. meningomyelocele (Saraç et al., 2016). Of note, dietary Mg²⁺ supplementation is common practice of pregnant women (Durlach et al., 2004). Our work provides first mechanistic insight as to how this essential mineral is delivered to the fetus.

There is growing evidence to suggest that Mg²⁺ deprivation is involved in the development of metabolic, immune, cardiovascular and neurological disorders (de Baaij et al., 2015). However, due to the lack of adequate mammalian genetic models, it is still unclear whether impaired Mg²⁺ homeostasis can be regarded as the cause or the consequence of the latter pathophysiological processes. Therefore, we studied the impact of *TRPM6* deletion on postnatal mice. *Trpm6*-deficient mice displayed shorter lifespans, failure to thrive, low physical activity, kyphosis, lung emphysema, sarcopenia and degeneration of lymphoid organs. In addition, *Trpm6*-deficient animals developed signs of catabolic metabolism such as lipodystrophy, increased insulin sensitivity and hypothermia, and showed suppression of the somatotrophic axis accompanied by induction of xenobiotic detoxification gene networks in the liver. Altogether, we noted that the complex phenotype of *Trpm6*-deficient mice mirrors many phenotypic hallmarks of mutant mouse strains that are generally considered genetic models of ‘accelerated aging’ in the scientific literature (López-Otín et al., 2013). Furthermore, our unbiased screen for metabolic pathways dysregulated in *Trpm6*-deficient mice revealed an error in energy metabolism reminiscent of humans with mutations in the gene coding for mitochondrial carnitine palmitoyltransferase II, the most common inherited disorder of lipid metabolism in adult humans (Bonfont et al., 2004; Gempel et al., 2002). Interestingly, an early biochemical study revealed that Mg²⁺ and MgATP could regulate activity of mitochondrial carnitine acyltransferase activity (Saggerson, 1982). Accordingly, in proof-of-concept experiments, we demonstrated that Mg²⁺ is specifically required for the utilization of acyl carnitines (AC) as an energy source in liver mitochondria. Hence, these results suggest that insufficient mitochondrial utilization of AC represents a plausible mechanism contributing to the pathologies developed by *Trpm6*-deficient mice. The exact role of Mg²⁺ in AC metabolism as well as the molecular pathophysiology of carnitine

palmitoyltransferase II deficiency is still not completely understood and, being beyond of the scope of the current manuscript, has to be addressed in future studies.

Notably, if *Trpm6*-deficient mice were fed with a high Mg^{2+} diet, they were viable and displayed normal physical activity, morphology of internal organs and tissue levels of AC, indicating that the phenotypes in *Trpm6*-deficient mice were triggered by Mg^{2+} deficiency. Therefore, we studied in more detail how mutant mice develop organismal Mg^{2+} deprivation. According to current thinking, the active transport of Mg^{2+} in the kidney, in particular in DCT, determines the final urinary Mg^{2+} concentration and is central to whole-body Mg^{2+} balance (*de Baaij et al., 2015*). Contrary to this model, we demonstrate that global inactivation of *Trpm6* leads to Mg^{2+} deficiency due to a defect in intestinal Mg^{2+} uptake. To interrogate the renal role of TRPM6, we conditionally inactivated *Trpm6* in the kidney and, surprisingly, did not observe any changes in serum Mg^{2+} levels. In contrast, intestine-specific disruption of *Trpm6* resulted in hypomagnesemia indicating that wildtype kidneys were not able to counterbalance the ablation of TRPM6 in the intestine. Taken together, our findings lend strong support to the new concept that *Trpm6*-dependent Mg^{2+} uptake by the colon plays an indispensable role for systemic Mg^{2+} balance in mice. However, we assume that renal TRPM6 activity may have an important role under conditions of insufficient dietary Mg^{2+} intake, for instance, during prolonged fasting periods.

Currently there are two suggested mechanistic models of hypomagnesemia in humans carrying mutations in *TRPM6*. A pioneering study of patients with congenital hypomagnesemia anticipated that Mg^{2+} malabsorption in the intestine plays a key role in organismal Mg^{2+} deprivation (*Friedman et al., 1967; Milla et al., 1979*). More recently, it was reported that in affected humans renal Mg^{2+} loss plays a key role (*Schlingmann et al., 2002; Walder et al., 2002*). The results obtained with *Trpm6*-deficient mice are well compatible with the former model. However, we cannot exclude physiological differences between humans and mice, an important issue to address in future studies. In conclusion, our findings support the idea that TRPM6 is a central gatekeeper of organismal Mg^{2+} balance in mammals and that this role cannot be compensated for by any other Mg^{2+} channel and transporter.

What is the molecular mechanism underlying insufficient Mg^{2+} intake in *Trpm6*-deficient mice? TRPM6 and its close homolog TRPM7 have been invoked as molecular correlates of cation currents responsible for Mg^{2+} entry into cells. In order to circumvent the limitations and pitfalls imposed by overexpression of recombinant proteins, we employed TS cells to compare the roles of native TRPM6 and TRPM7. We found that stem cells express both TRPM6 and TRPM7, thus mimicking the *in vivo* situation. Inactivation of *Trpm6* did not affect the self-renewal of TS cells. In contrast, *Trpm7*-deficient cells were not able to proliferate unless the cell culture medium was supplemented with additional Mg^{2+} , supporting the idea that TRPM7 plays a non-redundant role in cellular Mg^{2+} uptake (*Schmitz et al., 2003; Chubanov et al., 2004; Ryazanova et al., 2010*). We further showed that wildtype TS cells exhibited $[Mg^{2+}]_i$ - and $[MgATP]_i$ -sensitive divalent cation currents, and that inactivation of *Trpm6* reduced current amplitudes. In contrast, deletion of TRPM7 caused complete ablation of these currents. Remarkably, ion currents in *Trpm6* deficient TS cells still expressing TRPM7 were substantially more sensitive to intracellular MgATP when compared to TRPM6/M7 co-expressing cells. Thus, in a native environment the presence of TRPM6 reduces the sensitivity of TRPM6/M7-like currents to inhibition by intracellular MgATP. It has recently been reported that the TRPM6/M7 heteromer is completely insensitive to MgATP after heterologous expression in HEK 293 cells (*Zhang et al., 2014*). Thus, native TRPM6/M7 currents do not fully recapitulate the latter findings obtained in a heterologous expression system and further studies are required to clarify these discrepancies. Nevertheless, our results are concordant with our model (*Chubanov et al., 2004*) that native TRPM6 functions primarily as a subunit of heteromeric TRPM6/M7 complexes by increasing current amplitudes and relieving TRPM7 from inhibition by $[MgATP]_i$ (*Figure 6G*). Such facilitated Mg^{2+} entry is most probably not required for any cell autonomous function, but is necessary for epithelial Mg^{2+} transport and the maintenance of serum Mg^{2+} levels.

Inadequate nutritional Mg^{2+} intake is commonplace in Western societies (in up to 68% of the US population [*King et al., 2005*]). In addition, a growing percentage of the population is exposed to drug-induced forms of hypomagnesemia (*de Baaij et al., 2015*). Consequently, we asked whether wildtype mice would benefit from extra Mg^{2+} supplementation. Our proof-of-concept experiments suggest that life-long Mg^{2+} supplementation may extend the lifespan of mice. This idea is concordant with the recent observation that Mg^{2+} acting alone or in conjunction with dietary calorie

restriction counteracts lifespan-shortening effects of RNA-DNA hybrid (R loop) accumulation in yeasts and human HeLa cells (Abraham *et al.*, 2016). Hence, large-scale investigations of nutritional Mg^{2+} adjustments and their impact on health- and lifespan of different species should be enlightening in this regard.

Materials and methods

Mouse strains

Experiments involving animals were done in accordance with the EU Animal Welfare Act and were approved by the local councils on animal care (permit No 55.2-1-54-2532-134-13 from the Government of Oberbayern, Germany, and permit No 2347-15-2014 from the State Ministry of Brandenburg, Germany).

Trpm6 gene-trap mutant mouse strain

A mouse line carrying a gene-trap mutation in *Trpm6* (129S5/SvEvBrd-C57BL/6) (Woudenberg-Vrenken *et al.*, 2011) was obtained from the Texas Institute for Genomic Medicine (stock No. TG0020; RRID:IMSR_TAC:tf0834). In the mutant allele (*Trpm6* ^{β geo}), exons 2 and 3 of *Trpm6* were replaced by a β geo reporter sequence (β geo). The β geo cassette includes a splice acceptor site sequence (SP), a bacterial β -galactosidase marker (*LacZ*), an internal ribosome entry site (*IRES*) and a neomycin resistance sequence (*NeoR*). Consequently, the *Trpm6* ^{β neo} allele drives the expression of an aberrant transcript encoding only exon 1 of *Trpm6* spliced to β geo. In order to obtain the *Trpm6* ^{β geo} allele in a C57BL/6J genetic background, *Trpm6* ^{β geo/+} 129S5/SvEvBrd-C57BL/6 mice were backcrossed with C57BL/6J mice for six generations. Mice were genotyped using PCR analysis of genomic DNA isolated from tail fragments. DNA was extracted and purified using the GenElute mammalian genomic DNA isolation kit (Sigma-Aldrich). DNA samples were examined by PCR using a set of allele-specific oligonucleotides (Metabion) and REDTaq DNA polymerase (Sigma-Aldrich). *Trpm6* ^{β geo} allele was analyzed using primers *Trpm6* ^{β geo}-Forward 5'-GCGTTGGCTACCCGTGAT-3' and *Trpm6* ^{β geo}-Reverse 5'-CTGATAAGGAAGGCTGCTCTAAG-3' with PCR settings: 94°C 3', 94°C 30'', 55°C 30'', 72°C 1', 40 cycles, 72°C 5'. The amplified PCR product (367 bp) was visualised by standard agarose gel electrophoresis and confirmed by sequencing.

Mice with a conditional *Trpm6* (*Trpm6*^{fl}) allele

A mouse line (C57BL/6) carrying a conditional mutation in *Trpm6* was generated by Taconic Artemis (Köln, Germany). Mouse genomic fragments corresponding to the targeted *Trpm6* segment were obtained from the C57BL/6J RPCIB-731 BAC library. The mutant locus contained two intronic LoxP sites flanking exon 17 of *Trpm6*. In addition, the targeting construct contained thymidine kinase (TK) and neomycin resistance (*NeoR*) markers allowing for negative and positive selection of mutant ES clones. *NeoR* was flanked by additional FRT recombination sites allowing for the subsequent deletion of *NeoR* sequences using Flp recombinase. BAC fragments, recombination sites, *NeoR* and TK were assembled in the targeting vector using an ET-cloning approach. The final targeting construct was confirmed by sequencing. C57BL/6N Tac embryonic stem (ES) cells were grown on mitotically inactive mouse embryonic fibroblasts (MEF) in DMEM (high glucose) containing 20% FBS (PAN) and 1200 μ g/mL leukemia inhibitory factor (Millipore). The authentication of ES cells was performed by Taconic Artemis and no further authentication was performed by the authors. 10^7 ES cells were electroporated (Biorad Gene Pulser) with 30 μ g linearized targeting vector. G418 (200 μ g/mL) selection was started on day 2 and counter-selection with gancyclovir (2 μ M) was started on day 5 after electroporation. ES clones obtained were examined for homologous recombination and single integration by Southern blotting (SB) using two probes located in 3' and 5' arms of the targeting construct and one additional probe located in *NeoR*. Sequences of the targeting vector, probes and SB images are available upon request. Mutant ES cells (clone 3339-AG-1) were injected into blastocysts isolated from uteri of 3.5 days post coitum (dpc) BALB/c females. The injected blastocysts were transferred to uteri of 2.5 dpc pseudopregnant females. Chimerism of the offspring obtained (G0) was evaluated by coat colour contribution (white/black). Highly chimeric G0 males were crossed with C57BL/6 females carrying a ubiquitously expressed *Flp* transgene to delete the *NeoR* cassette from

the mutant locus. Germline transmission in G1 offspring was identified by the presence of black coat colour followed by PCR analysis of genomic DNA isolated from tail fragments.

Deletion of exon 17 using Cre recombinase results in a frame-shift in the *Trpm6* transcript. The efficiency of Cre-mediated deletion of the floxed exon 17 (referred to as *Trpm6*^{Δ17} allele) was examined using females ubiquitously expressing the *Sox2-Cre* transgene. The maternally inherited *Sox2-Cre* transgene allows for efficient recombination of LoxP-flanked genomic sequences in the single-cell embryo (*Hayashi et al., 2003*). This approach was employed to produce *Trpm6*^{Δ17/+} individuals (**Table 1**). Mice were genotyped using PCR analysis of genomic DNA isolated from the tail fragments as described above for *Trpm6*^{βgeo/+} mice. *Trpm6*⁺ allele was analyzed using primers *Trpm6*⁺-Forward 5'-AGAGACGTGCAGTGTAGGACAGAG-3' and *Trpm6*⁺-Reverse 5'-ACGGCACACAGAAAA-CACCAG-3' with PCR settings: 94°C 3', 94°C 30'', 64°C 30'', 72°C 1', 40 cycles, 72°C 5' (PCR product 549 bp). *Trpm6*^{fl} allele was studied using primers *Trpm6*^{fl}-Forward 5'-GCAAATACAAGCAACACCTCC-3' and *Trpm6*^{fl}-Reverse 5'-GAAGTTCCTATTCCGAAGTTC-3' with PCR settings: 94°C 3', 94°C 30'', 53°C 30'', 72°C 1', 40 cycles, 72°C 5' (PCR product 368 bp). *Trpm6*^{Δ17} mutation was determined using primers *Trpm6*^{Δ17}-Forward 5'-TGTCTCCATGTTGCTACGA-3' and *Trpm6*^{Δ17}-Reverse 5'-CTCCGGTCCACAGTTCAT-3' with PCR settings: 94°C 3', 94°C 30'', 53°C 30'', 72°C 1', 40 cycles, 72°C 5' (PCR product 362 bp). Amplified PCR products were confirmed by sequencing.

Mice with organ-restricted inactivation of *Trpm6*

Transgenic mice expressing Cre recombinase under the control of the mouse *Sox2* promoter (*Sox2-Cre* mice, C57BL/6J; RRID:IMSR_HAR:3359) (*Hayashi et al., 2003*), *Kidney-specific/Cadherin16* promoter (*Ksp-Cre* mice, C57BL/6J; RRID:MGI:4452131) (*Shao et al., 2002*) and *Villin1* promoter (*Villin1-Cre* mice, C57BL/6J; RRID:MGI:3581405) (*Madison et al., 2002*) were obtained from the Jackson Laboratory (Sacramento, CA, USA, stock No. 008454, 012237, and 004586 respectively). To conditionally inactivate *Trpm6*, *Sox2-Cre*, *Ksp-Cre* and *Villin1-Cre* mice were crossed with *Trpm6*^{Δ17/+} mice to produce *Trpm6*^{Δ17/+;Sox2-Cre}, *Trpm6*^{Δ17/+;Ksp-Cre}, and *Trpm6*^{Δ17/+;Villin1-Cre} males. Next, these males were bred with *Trpm6*^{fl/fl} females to generate offspring with a global, kidney and intestine-restricted disruption of *Trpm6* as outlined in **Table 1**. Inheritance of *Sox2-Cre*, *Ksp-Cre* and *Villin1-Cre* transgenes was determined by PCR analysis of tail DNA at conditions described previously (*Madison et al., 2002*; *Shao et al., 2002*; *Hayashi et al., 2003*).

Trpm7^{Δ17/+} mice

A mouse line carrying a conditional mutation in *Trpm7* (*Trpm7*^{fl/fl} mice, 129 S6/SvEvTac; RRID:IMSR_JAX:018784) was kindly provided by David Clapham, Harvard Medical School, Boston, USA. The mutant locus contains two intronic LoxP sites flanking exon 17 of the *Trpm7* gene. Deletion of exon 17 results in a frame-shift mutation (*Trpm7*^{Δ17} allele) and subsequent disruption of TRPM7. To produce *Trpm7*^{Δ17/+} mice, *Trpm7*^{fl/fl} females were crossed with *Sox2-Cre* males and the resulting offspring were genotyped by PCR as described previously (*Jin et al., 2008*). The generated *Trpm7*^{Δ17/+} strain was maintained by intercross of *Trpm7*^{Δ17/+} parents.

Housing, metabolic and behaviour profiling of mice

Housing conditions

Mice were kept in individually ventilated polycarbonate cages (IVC System, Tecniplast, Germany). Cages were changed weekly and were on a 12 hr light/dark cycle with artificial lighting. Temperature and relative humidity were 22 ± 1°C and 50 ± 5%, respectively. Breeding animals were maintained on a multigrain chow Ssniff M-Z (Ssniff GmbH, Germany) and drinking water containing 20.1 mg/l Mg²⁺ and 81.9 mg/l Ca²⁺ (*ad libitum*). Litters were weaned at three weeks of age, genotyped and desired littermates were housed in cages as described above except that a 'maintenance' chow Sniff R/M-H (Ssniff GmbH, Germany) was used. Both Ssniff M-Z and Ssniff R/M-H chows contained 0.22% Mg²⁺ and 1.0% Ca²⁺. In dietary Mg²⁺ supplementation experiments, 4 week-old *Trpm6*-deficient and control mice were fed Ssniff R/M-H chow containing 0.75% Mg²⁺ (Ssniff GmbH, Germany).

Collection of specimen

Mice were weighed, killed and blood samples were collected by a cardiac puncture technique. Blood samples were incubated 30 min at RT, clots were removed by centrifugation (Heraeus Pico 17, 3500

rpm for 30 min at RT) and the resulting serum samples were stored at -80°C . Internal organs were removed, flash frozen in liquid nitrogen and stored at -80°C . Right tibias were dissected, cleaned from muscle tissues, dried overnight at 70°C and kept at RT. To determine urinary and fecal excretion rates of main minerals, mice were maintained for 24 hr in individual metabolic cages (Acme Metal Products, USA) under housing conditions as described above and supplied ad libitum with drinking water and chow. After 24 hr, the urine and feces produced were collected. Urine samples were stored at -80°C . Feces specimen were dried overnight at 70°C and stored at -20°C .

Determination of Mg^{2+} levels and other main elements

Content of main elements in bones, serum, urine, feces and gastrocnemius muscle samples was determined by inductively coupled plasma mass spectrometry (ICP-MS) by ALS Scandinavia (Sweden) as reported previously (*Rodushkin and Odman, 2001; Rodushkin et al., 2004*).

Monitoring of food and water intake, locomotor activity, body lean mass, body temperature and energy content

Food and water intake were recorded with an automated Drinking and Feeding Monitor system (TSE Systems, Germany) with food baskets connected to weight sensors. An adaptation period of 2 days was followed by 3 days of data collection. Cumulative food intake and locomotor activity (based on infrared beams, InfraMot-Activity System, TSE Systems, Germany) were recorded. The core body temperature was measured using a rectal probe as reported previously (*Braun et al., 2009*). In vivo analysis of body lean mass was performed in conscious, restrained mice by nuclear magnetic resonance (EchoMRITM-100H; EchoMRI LLC, USA) weekly and before metabolic measurements. The energy content in feces was determined by bomb calorimetry (IKA C5003; IKA Werke, Staufen, Germany).

Evaluation of atherosclerosis development

Assessment of atherosclerosis lesions was performed as described previously (*van der Vorst et al., 2015*).

Determination of insulin growth factor 1 (IGF1), major urinary proteins (MUPs), β -hydroxybutyrate and glucose-tolerance test

Serum concentrations of IGF1 were analysed by a Mouse/Rat IGF-I ELISA kit (R and D-Systems). MUPs content as assessed by SDS-PAGE gel electrophoresis of $1\ \mu\text{l}$ urine samples from individual mice. β -Hydroxybutyrate was measured by a commercially available assay kit (Sigma-Aldrich). For a glucose-tolerance test, mice were fasted for 6 hr, followed by an oral gavage of glucose (2 mg/g body weight). Blood samples were collected via the tail vein and blood glucose levels were measured using a contour glucometer (Bayer, Germany). Plasma levels of insulin were measured using a commercially available ELISA kit (Alpco).

Histological examination of tissues

Hematoxylin-eosin staining of tissue sections

Tissues were fixed overnight at 4°C in 4% paraformaldehyde (PFA), dehydrated through a series of ethanol washes, cleared in three changes of xylene and embedded in paraffin. Tissue sections ($5\ \mu\text{m}$) were cut by RM2125 RTS microtome (Leica Microsystems, Germany), mounted on Superfrost Plus slides (Menzel-Gläser), and dried at 70°C for 1 hr. Tissue sections were dewaxed in xylene, rehydrated through a series of ethanol washes to deionized water. Slides were incubated in Mayers hematoxylin solution (Carl Roth) for 10 min at RT followed by incubation in 0.5% Eosin Y solution (Carl Roth) for 13 min at RT. The colour reaction was stopped by deionized water, slides were dehydrated in ethanol, cleared in xylene and mounted using mounting medium (Carl Roth). Slides were examined using an Olympus CX41 microscope and Cell Imaging software (Olympus, Germany).

Immunohistochemistry (IHC)

Polyclonal TRPM6-specific antibodies were raised by immunization of rabbits with H_2N -CERDK NRSSLEDHTRL-COOH peptide coupled via the N-terminus to keyhole limpet hemocyanin (KLH) and

purified by peptide affinity chromatography (Eurogentec, Belgium). Whole kidneys were dissected from eight week-old mice and embedded in Jung tissue freezing medium (Leica Microsystems, Germany). 10 μm cryosections were produced by a CM 3050S cryotom (Leica Microsystems, Germany), mounted on Superfrost Plus slides (Menzel-Gläser), air-dried for 20 min and fixed in 2% (w/v) paraformaldehyde in PBS (pH 7.4) for 20 min at RT. After washing in PBS (2 \times 10 min), sections were blocked with 5% goat serum/0.5% Triton X100 (Sigma-Aldrich) in PBS for 2 hr at RT. The rabbit anti-TRPM6 antibody (1 $\mu\text{g}/\text{ml}$ in 5% goat serum/0.5% Triton X100/PBS) was applied overnight at 4°C. Afterwards sections were washed in PBS (3 \times 10 min, RT) and a goat anti-rabbit antibody conjugated with Alexa 488 (Life Technologies, Darmstadt, Germany; 1 $\mu\text{g}/\text{ml}$ in 5% goat serum/PBS) was applied for 1 hr at RT. After washing in PBS (3 \times 10 min, RT), sections were embedded in Dako Mounting Fluid (Dako Cytomation). Differential interference contrast and confocal images were obtained with a confocal laser scanning microscope LSM 540 META (Carl Zeiss, Germany). We used a Plan-Apochromat x63/1.4 oil objective, the 488 nm excitation wavelength of an argon laser, and a 505–570 nm band-pass filter. Acquired DIC and confocal images were analysed using the LSM 540 META software (Carl Zeiss, Germany).

In situ hybridization (ISH)

cDNA templates for the production of cRNA *Trpm6* probes were produced by PCR with the following 2 sets of primers: Probe-1-Forward: 5'-aattaaccctcactaaagggGAGAGGAGGCCACAGTCAAG-3'; Probe-1-Reverse: 5'-taatacactcactatagggGCTCAAAGACGATGTCACGA-3'; Probe-2-Forward: 5'-aattaaccctcactaaagggCCTGTCAAAGAAGAAGAGGAA-3'; Probe-2-Reverse: 5'-taatacactcactatagggAGAAAAGACTTCACAATG-3'. Primers contained T7 (reverse primer lower case) or T3 (forward primer lower case) RNA polymerase sites. PCR products were gel purified (Qiagen Gel Extraction Kit) and sequence verified (ARGF). Digoxigenin (DIG) labelled cRNA probes were synthesized according the manufacturer's instructions (Roche, 10x DIG RNA labelling kit). Both probe sets produced similar results on $n = 5$ placentas at each gestational time point examined, and $n = 3$ WT kidney or intestinal samples. *Gcm1* and *SynA* riboprobes were described previously (Dawson et al., 2012). Preparation of tissue sections and ISH procedures were performed as previously described (Dawson et al., 2012). Slides were imaged by an Aperio slide scanner and analysed using ImageScope software.

Whole-genome profiling of the liver transcriptome in *Trpm6*-deficient mice

Microarray data were deposited in NCBI Gene Expression Omnibus (GEO) (GSE70457). Liver tissues were collected from 12–13 week-old *Trpm6*-deficient (*Trpm6* ^{Δ 17/ Δ 17}; *Sox2-Cre*, $n = 3$) and control (*Trpm6*^{+/^{fl}}, $n = 4$) male littermates, snap-frozen in liquid nitrogen and stored at -80°C . Total RNA was extracted using the GenElute mammalian total RNA purification kit (Sigma-Aldrich). Whole genome profiling was performed using a GeneChip Mouse Gene 1.0 ST Array (Affymetrix) at Source Bioscience (Berlin, Germany). Biotinylated single-stranded DNA was prepared according to the standard Affymetrix protocol (Whole Transcript Expression arrays) from 100 ng total RNA using the WT terminal labelling kit. 2.5 μg of fragmented and labelled ssDNA were hybridized for 16–18 hr at 45°C. GeneChips were washed and stained in an Affymetrix Fluidics Station 450. GeneChips were scanned using the Affymetrix GeneChip Scanner 3000. Processing of the array data, including quality assessment, background correction, normalization and summarization was performed with the Affymetrix Expression Console (version 1.4.0). All statistical analyses were carried out with the statistical computing environment R (version 3.1.2, www.R-project.org). Differential expression analysis was performed with the R package limma (version 3.22.4) (Ritchie et al., 2015). p-values were adjusted for multiple testing with the Benjamini-Hochberg method for controlling the false discovery rate (FDR). A heatmap was generated for a group of 46 transcripts differentially expressed at a level of FDR $p \leq 0.1$. Analysis of the affected pathways and causal transcriptional regulators was performed by Ingenuity pathway analysis (IPA) environment (www.ingenuity.com, RRID:SCR_008653) using a set of 2443 transcripts changed at $p \leq 0.05$ confidence level (t-test).

Metabolomic profiling of serum, liver and skeletal muscle in *Trpm6*-deficient mice

Serum, liver and gastrocnemius muscle samples were collected from 8–10 week-old control (*Trpm6*^{fl/fl}, n = 8) and *Trpm6*-deficient (*Trpm6*^{Δ17/Δ17;Sox2-Cre}, n = 6) male littermates, flash frozen in liquid nitrogen and stored at –80°C. Metabolomic analyses were performed at Biocrates Life Sciences AG (Innsbruck, Austria). Measurements comprised the quantification of 237 metabolites including 41 amino acids/biogenic amines, 40 acylcarnitines (AC), 22 bile acids (BA), 14 lysophosphatidylcholines (LysPC), 77 phosphatidylcholines (PC), 15 sphingomyelins (SM), 17 eicosanoids/prostaglandins and 11 energy metabolism intermediates as outlined in **Supplementary file 3**. To extract metabolites, tissue samples were treated with corresponding extraction buffers and incubated in a chilled ultrasonic bath for 5 min. Afterwards samples were centrifuged and the supernatant was used for analysis. FIA- and LC-MS/MS measurement techniques were applied as described in detail previously (**Pena et al., 2014**). All statistical analyses have been applied by using the statistical computing environment R (www.r-project.org). Metabolite measurements containing more than 75% missing values or more than 75% of values below the limit of detection (LOD) across all samples per matrix were removed from analysis. Measured concentrations of metabolites were log₂-transformed for moderated statistical tests. Measurements were scaled to μ = 0 mean and unit standard deviation for each biological matrix separately for heatmap visualization. Changes in average metabolite levels between control and mutant individuals were tested using a linear model framework implemented in the R package Limma (**Smyth, 2004**). Resulting P-values for moderated t-test were corrected for multiple testing by Benjamini and Hochberg approach. A p-value threshold of 0.05 was considered as significant. A Heatmap diagram for metabolites with significant changes was calculated with the R-package Heatmap using ward clustering and Euclidean distance measure and the R-package VennDiagram was applied to calculate a Venn diagram of significantly changed metabolites across sample matrices.

Mitochondrial isolations and analyses

Mouse liver mitochondria were isolated by differential centrifugation from freshly prepared homogenates as previously described (**Springer et al., 2002; Schulz et al., 2015**). Liver mitochondria were further purified by Percoll density gradient centrifugation (**Schulz et al., 2013**). Isolated mitochondria were subjected to quantification by the Bradford assay and kept on ice until use. Assessment of the mitochondrial membrane potential Δψ_m (MMP) was followed by Rh123 fluorescence quenching (Ex. 485 nm, Em. 528 nm) in a 96-well plate reader (BioTek) and quantitatively evaluated by curve analysis as previously described (**Schulz et al., 2013**) (set threshold slopes were ≥0.67 for start points and ≤0.67 for end points, respectively). In order to exclude fluctuations at measurement start, slope calculations were started after 6 min measurement time with slope values ≤ 1.5. A kit-based assay (ATP Bioluminescence Assay Kit, Roche) was used to analyze the ATP content from cleared lysates after 30 min mitochondrial ATP synthesis at RT, initiated by the addition of 160 μM ADP and stopped at 95°C for 5 min. For both analyses assay buffer composition was 0.2 M sucrose, 10 mM MOPS-Tris, 1 mM Pi and 10 μM EGTA. Respiratory substrates were either succinate (25 mM)/rotenone (2 μM), or DL-octanoylcarnitine (10 μM)/malate (12.5 mM), or DL-palmitoylcarnitine (10 μM)/malate (12.5 mM). Buffers and solutions were essentially Mg²⁺-free, as determined by ICP-OES (Ciros Vision, SPECTRO Analytical Instruments GmbH) after wet ashing with 65% nitric acid (**Zischka et al., 2011**). EDTA, Mg²⁺, Ca²⁺, or Zn²⁺ was added at the concentrations indicated in the respective figures.

Isolation and characterization of mouse trophoblast stem (TS) cells

Isolation of TS cells

TS cells were isolated as described (**Tanaka et al., 1998**), with several modifications (**Erlebacher et al., 2004; Natale et al., 2009**). 3.5 days post-coitum blastocysts were isolated from *Trpm6*^{βgeo/+} parents. Individual blastocysts were incubated in a humidified cell culture incubator (Heraeus, Thermo Fisher Scientific) at 37% and 5% CO₂ for 3 days in 12 well plates (Sarstedt) containing 8 × 10⁴/well irradiated mouse embryonic fibroblasts (MEFs) (Millipore) in RPMI 1640 medium (Life Technologies) supplemented with 20% fetal bovine serum (ES type, Life Technologies), 1 mM sodium pyruvate (cell culture type, Sigma-Aldrich), 100 μM β-mercaptoethanol (Sigma-Aldrich), 50

$\mu\text{g/ml}$ streptomycin and 50 U/ml penicillin (all from Life Technologies), 1.0 $\mu\text{g/ml}$ heparin (cell culture type, Sigma-Aldrich), 25 ng/ml human recombinant FGF4 (R and D systems), 5 ng/ml human recombinant TGF- β 1 (R and D systems), 10 ng/ml recombinant activin A (R and D systems) and an additional 10 mM MgCl_2 . The attached embryos were disaggregated by 0.05% trypsin-EDTA (Life Technologies) and derived cells were further co-cultured with MEFs as described above. The obtained TS cells were propagated and adapted to MEF-free conditions without additional Mg^{2+} in the culture medium. The authentication of TS cells was based on expression of a trophoblast stem cell marker *Esrrb*, characteristic morphological appearance and ability to proliferate only in the presence of FGF4 and TGF- β 1 (Tanaka et al., 1998; Simmons and Cross, 2005). TS cells were tested negative for mycoplasma contamination using QuickTest kit (Biotool).

Genotypes of TS cells were determined by PCR analysis of genomic DNA using conditions described above for *Trpm6* ^{$\beta\text{geo}/+$} mice. TS cells were further examined by RT-PCR. Total RNA was extracted from TS cell pellets using the GenElute mammalian total RNA purification kit (Sigma-Aldrich). First strand cDNA synthesis was performed by RevertAid H minus reverse transcriptase (Thermo Scientific). PCR was performed using REDTaq DNA polymerase (Sigma-Aldrich) with two primer sets: *Trpm6a*-Forward 5'-GCTGCCAAATCTGCCACAAT-3' and *Trpm6a*-Reverse 5'-TGCCCCA-CAGTCCCATCATCACA-3' or *Trpm6b*-Forward 5'-CCAGCTCAAAGACCCTCACAGATGC-3' and *Trpm6b*-Reverse 5'-CACACCACATCTTTCCGACCAG-3'. The following PCR conditions were used: 94°C 3', 94°C 30'', 56°C 30'', 72°C 1', 35 cycles, 72°C 5'. Amplified PCR products were 651 bp or 586 bp, respectively. Self-renewal of *Trpm6* ^{$\beta\text{geo}/\beta\text{geo}$} TS cells was assessed by determination of DNA content as described previously (Tanaka et al., 1998). Briefly, TS cells were cultured for 3 days, dissociated by trypsin-EDTA and fixed with 40% ice-cold ethanol. Fixed TS cells were incubated in propidium iodide (PI) staining solution (50 $\mu\text{g/ml}$ PI, 0.2 mg/ml RNaseA in PBS, all from Sigma-Aldrich) for 30 min at RT. Stained cells were dissolved in PBS and examined using BD FACSCalibur (BD Biosciences, Germany) and FlowJo software (www.flowjo.com).

Trpm7-deficient and corresponding control TS cells were derived as described above using *Trpm7* ^{$\Delta^{17}/+$} mice. The obtained *Trpm7* ^{$+/+$} and *Trpm7* ^{Δ^{17}/Δ^{17}} TS cells were propagated and adapted to MEF-free conditions in cell culture medium supplemented with 10 mM MgCl_2 . Genotypes of TS cells were determined by PCR analysis of genomic DNA using conditions described for *Trpm7* ^{$\Delta^{17}/+$} mice. The lack of *Trpm7* transcripts in *Trpm7* ^{Δ^{17}/Δ^{17}} TS cells was verified by RT-PCR using primers *Trpm7*-Forward 5'-AGTAATTCAACCTGCCTCAA-3' and *Trpm7*-Reverse 5'-ATGGGTATCTCTTCTG TTATGTT-3' and the following PCR conditions: 94°C 3', 94°C 30'', 50°C 30'', 72°C 1', 35 cycles, 72°C 5'. The amplified PCR product was 287 bp.

To study growth rates, TS cells of each genotype were seeded in 6-well plates (1×10^5 cells/well) in cell culture medium containing 10 mM MgCl_2 . After 24 hr (day 1), the culture medium was replaced with fresh medium either with or without 10 mM MgCl_2 and the cells were further cultured for additional 3 days. The cell density was determined at 24 hr intervals using a Neubauer chamber (Marienfeld Superior). To calculate growth rates, the cell number at day 1 was designated as 100%. The experiment was repeated three times and a Student's *t*-test was applied to compare the growth rates of control versus mutant cells.

Electrophysiology

Whole-cell currents were measured using an EPC10 patch-clamp amplifier and PatchMaster software (Harvard Bioscience, Germany). Voltages were corrected for a liquid junction potential of 10 mV. Currents were elicited by a ramp protocol from -100 mV to $+100$ mV over 50 ms acquired at 0.5 Hz and a holding potential of 0 mV. Inward and outward current amplitudes were extracted at -80 mV and $+80$ mV and were normalized to cell size as pA/pF. Capacitance was measured using the automated capacitance cancellation function of EPC10. Patch pipettes were made of borosilicate glass (Science Products) and had resistances of 2–3.5 M Ω . The standard extracellular solution contained (in mM): 140 NaCl, 3 CaCl₂, 2.8 KCl, 10 HEPES, and 11 glucose (all from Sigma-Aldrich). A divalent-free (DVF) extracellular solution contained (in mM): 140 NaCl, 2.8 KCl, 10 HEPES, 11 glucose and 5 EDTA. TRPM6/M7-like currents were induced by Mg^{2+} -free intracellular solution, containing (in mM): 140 Cs-glutamate, 8 NaCl, 10 EGTA, 5 EDTA and 10 HEPES. All solutions were adjusted to pH 7.2 using a FE20 pH-meter (Mettler Toledo, Germany). The osmolality of all solutions was adjusted to

290 mOsm using Vapro 5520 osmometer (Wescor Inc., USA). Data were compared by an unpaired Student's *t*-test.

For Mg^{2+} ($[Mg^{2+}]_i$) and MgATP ($[MgATP]_i$) dose responses, the intracellular pipette solution contained (in mM): 120 Cs-glutamate, 8 NaCl, 10 HEPES, 2.7 EDTA and various amounts of $MgCl_2$ or MgATP (Sigma-Aldrich). The solutions were adjusted to pH 7.2 and 290 mOsm. Concentrations of MgATP and free Mg^{2+} were calculated using WebMaxC (maxchelator.stanford.edu). To determine IC_{50} values, datasets were fitted using a nonlinear (least-squares) regression analysis (GraphPad Prism 6.0 software) and the following equation:

$$E(c) = E_{min} + (E_{max} - E_{min}) / (1 + 10^{((IC_{50} - C)h)})$$

with *E* being the effect/current at a given concentration *C* of inhibitor, E_{min} the minimal effect/current, E_{max} the maximally achievable effect, IC_{50} the half-maximal concentration and *h* the Hill slope factor. Statistical analysis of dose-response curves and IC_{50} values was performed using the extra sum-of-squares *F* test with the threshold *P* value 0.05 (GraphPad Prism 6.0).

Characterization of *TRPM7*-deficient human haploid leukaemia (HAP1) cells

Isolation and maintenance of *TRPM7*-deficient HAP1 cells

Wildtype parental cells (clone C631) and *TRPM7*-deficient (clone 10940-04) HAP1 cells were acquired from Horizon Genomics (Vienna, Austria). The authentication of HAP1 cells was performed by Horizon Genomics (*Essletzbichler et al., 2014*) and no further authentication was performed by the authors. A CRISPR/Cas9 approach was used to introduce a 17 bp (GTGACCATTTTAATCAG) deletion in exon 4 of the human *TRPM7* gene resulting in a frame-shift mutation. Genotypes of HAP1 cells were confirmed by PCR amplification of genomic DNA using primers hTRPM7-Forward 5'-TATTTGTATGCACCTTTGTA-3' and hTRPM7-Reverse 5'-TGTTTTAATCTCACCTTTTT-3' with PCR parameters: 94°C 3', 94°C 30'', 50°C 30'', 72°C 1', 40 cycles, 72°C 5'. PCR products (364 bp and 347 bp in wild type and mutant clones, respectively) were confirmed by sequencing. HAP1 cells were tested negative for mycoplasma contamination using QuickTest kit (Biotool).

HAP1 cells were cultured in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% FBS and 100 U/ml penicillin, 100 µg/ml streptomycin and 10 mM $MgCl_2$ (all from Thermo Fisher Scientific). Cells were maintained in a humidified cell culture incubator (Heraeus, Thermo Fisher Scientific) at 37°C and 5% CO_2 . Western blot analysis was performed as described previously (*Nörenberg et al., 2016*). Examinations of growth rates and endogenous *TRPM7*-like currents were conducted as described above for TS cells.

Determination of total Mg^{2+} content

HAP1 cells of each genotype were grown in T175 cm² flasks (Sarstedt) in 10 mM $MgCl_2$ supplemented cell culture medium as described above. At ~50% confluence the medium was replaced with fresh medium without 10 mM $MgCl_2$ and the cells were cultured for additional 24 hr. Next, cells were washed with PBS, disaggregated by trypsinization and collected in 50 ml plastic tubes (Sarstedt). After centrifugation (3 min, 1000 rpm), the cell pellet was resuspended in 1 ml PBS and passed to a fresh 1.5 ml tube. The cell suspension was centrifuged (3 min, 3500 rpm), supernatant was completely removed and the cell pellet was dried overnight at 70°C. The dried cell pellet was analysed by ICP-MS in ALS Scandinavia (Sweden). The experiment was repeated four times.

Assessment of ATP levels

HAP1 cells of each genotype were seeded in 96-well plates (white wall/clear bottom, type 3610, Costar) at a density of 5×10^5 cells/well in the 10 mM $MgCl_2$ supplemented cell culture medium (100 µl/well); eight wells per genotype were used. After 24 hr, the cell culture medium was replaced with fresh regular medium (without additional 10 mM Mg^{2+}) and the cells were cultured for additional 24 hr. To determine cell viability, 10 µl of CCK-8 reagent (Cell Counting Kit-8) was added in four wells per genotype. The plates were incubated for 3 hr in the cell culture incubator (Heraeus, Thermo Fisher Scientific) at 37°C and 5% CO_2 . Next, 96-well plates were incubated at room temperature (RT) for 30 min and 100 µl of CellTiter-Glo2.0 reagent (Promega) was added to the remaining four wells per genotype. After 10 min incubation at RT, either ATP-induced luminescence or CCK-8

absorbance (450 nm) were determined using a plate reader (FLUOstar Omega, BMG Labtech). CCK-8 absorbance was used to normalize ATP-induced bioluminescence. The normalized bioluminescence of wildtype cells was designated 100%. The experiment was repeated six times.

High-resolution respirometry of living HAP1 cells

Oxygen consumption of HAP1 cells was assessed by Oxygraph-2k measurements (Oroboros Instruments GmbH, Austria) as described previously (*Pesta and Gnaiger, 2012*). Briefly, WT and KO HAP1 cells were maintained in standard medium supplemented by 10 mM MgCl₂. The Mg²⁺ supplemented medium was replaced with regular medium (without additional 10 mM Mg²⁺) and the cells were cultivated for a further 24 hr. Next, oxygen flux from routine respiration of 1.5×10⁶ cells at 37°C and maximal oxygen flux after stepwise CCCP addition (2 μl steps from 1 mM stock solution) were determined. The oxygen flux was baseline-corrected for non-mitochondrial oxygen consuming processes by the addition of 0.5 μM rotenone (complex I inhibitor, Sigma-Aldrich) and 2.5 μM antimycin A (complex III inhibitor, Sigma-Aldrich).

Whole-life dietary treatments of B6C3F1 mice

Mice were raised in a specific pathogen-free facility at Jackson Laboratory Sacramento (Sacramento, CA, USA). The long-lived B6C3F1 hybrid strain (*Lipman et al., 1999; Turturro et al., 1999*) was used. Specifically, F1 females were derived by crossing C57BL/6J females with C3H/HeJ males. The produced B6C3F1 females were weaned at 3 weeks of age, and afterwards kept in individually ventilated polycarbonate cages (Thoren Caging Systems) on multigrain chow 5 K54 (Purina) containing 0.22% Mg²⁺ and drinking water containing 0.44 mg/l Mg²⁺. Five mice were housed per cage and cages were changed every two weeks. The housing rooms were with artificial lighting and 12 hr light/dark cycle (6 am to 6 pm). Temperature and relative humidity in animal rooms were 22 ± 4°C and 50 ± 15%, respectively. At 5 months of age, mice were assigned to control, dietary restricted (DR) or supplemented cohorts as outlined in **Table 2**. For supplementation experiments, corresponding salts (Sigma-Aldrich) were diluted in drinking water that was administered *ad libitum* throughout the lifespan of all groups (**Table 2**). To reduce bias, the supplemented and control groups were examined simultaneously and the study was performed as a blinded trial. Mice were inspected daily. Necropsies of randomly selected dead mice revealed that 58 of 88 control females (66%) developed tumours. 8 of 11 females (73%) from the three Mg²⁺ supplemented groups also had tumours suggesting that high dietary Mg²⁺ had no substantial effect on tumor rate at death. Kaplan-Meier survival distributions were computed to illustrate survival times. For statistical analysis, we used MATLAB computing environment and programming language (MathWorks, www.de.mathworks.com), in particular its built-in fast convolution function that allows to find the distribution of the sum of independent random variables, given the distributions of individual variables. To enable statistical comparisons between control and dosed groups, the distribution of the mean lifespan of 15 control mice was found as a convolution of the original distribution of lifespans of all control mice. To calculate P-values of the mean lifespan from the dosed groups relative to the control group, we calculated the probability of the average of 15 control mice showing the same or more extreme (away from control mean) lifespan than the experimentally determined mean lifespan of the dosed mice. A similar technique was used to find P-values for pooled Mg and dietary restriction groups relative to controls. The MATLAB code is available from the Dryad Digital Repository (*Chubánov and Guder-mann, 2016*). In addition, the survival data of control mice versus individual treated groups were assessed by log-rank test using GraphPad Prism software. P-values for both approaches are indicated in **Figure 7A**.

Acknowledgements

We thank Jackson Laboratory Sacramento for the help with whole-life dietary treatments of mice. We thank David Clapham for providing *Trpm7^{fl/fl}* mice; Ilia Rodushkin for the support in ICP-MS; Marc Freichel and Petra Weißgerber for their help to isolate TS cells; Fabian Bamberg and Mike Notohamiprodjo for the help with X-ray imaging of mice; Sabine Schmitt for the help with high-resolution respirometry. We thank Renate Heilmair and Joanna Zaißerer for technical assistance. VC, SZ and TG were supported by the Deutsche Forschungsgemeinschaft, TRR 152. WJ and AS were supported by the German Federal Ministry of Education and Research (BMBF, DZD). SZ was supported

by Marie-Curie Fellowship (REA) FP7-PEOPLE-2012-CIG. EPCV and WC were supported by the Deutsche Forschungsgemeinschaft (SFB1123-A1) and German Centre for Cardiovascular Research (MHA VD1.2).

Additional information

Funding

Funder	Grant reference number	Author
Deutsche Forschungsgemeinschaft	TRR 152-P15	Vladimir Chubanov Thomas Gudermann
Deutsche Forschungsgemeinschaft	SFB1123-A1	Emiel PC van der Vorst Christian Weber
Deutsche Forschungsgemeinschaft	TRP 152-P14	Susanna Zierler
Seventh Framework Programme	Marie-Curie Fellowship FP7-PEOPLE-2012-CIG	Susanna Zierler

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

VC, TG, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article, Contributed unpublished essential data or reagents; SF, AW, CL, CE, WJ, HB, AB, BA, LM, LS, EPCvdV, Acquisition of data; DGS, AGR, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article; YS, Acquisition of data; Analysis and interpretation of data; FT, VJ, CW, Analysis and interpretation of data; ÖAY, KS, Acquisition of data, Analysis and interpretation of data; AS, HZ, Conception and design, Acquisition of data, Analysis and interpretation of data; SZ, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article

Author ORCIDs

Vladimir Chubanov, <http://orcid.org/0000-0002-6042-4193>

David G Simmons, <http://orcid.org/0000-0002-4115-9371>

Susanna Zierler, <http://orcid.org/0000-0002-4684-0385>

Ethics

Animal experimentation: Experiments involving animals were done in accordance with the EU Animal Welfare Act and were approved by the local councils on animal care (permit No 55.2-1-54-2532-134-13 from Government of Oberbayern, Germany, and permit No 2347-15-2014 from State Ministry of Brandenburg, Germany).

Additional files

Supplementary files

- Supplementary file 1. Whole genome profiling of hepatic transcripts altered in *Trpm6*-deficient mice. Dataset is available in the Dryad Digital Repository (**Chubanov and Gudermann, 2016**). (1) Genome-wide analysis of hepatic transcriptome in control vs *Trpm6*-deficient mice. (2) Up- and down-regulated transcripts in the liver of *Trpm6*-deficient mice with the false discovery rate (FDR) $p \leq 0.1$.

DOI: [10.7554/eLife.20914.022](https://doi.org/10.7554/eLife.20914.022)

- Supplementary file 2. Ingenuity Pathway Analysis (IPA) analysis of hepatic transcripts altered in *Trpm6*-deficient mice. Dataset is available from the Dryad Digital Repository (**Chubanov and Gudermann, 2016**). (1) IPA Canonical Pathways representing differentially expressed genes in the

liver of *Trpm6*-deficient mice. (2) IPA Causal Networks for differentially expressed genes in the liver of *Trpm6*-deficient mice.

DOI: [10.7554/eLife.20914.023](https://doi.org/10.7554/eLife.20914.023)

• Supplementary file 3. Metabolic profiling of the serum, liver and gastrocnemius muscle of *Trpm6*-deficient mice. Dataset is available in the Dryad Digital Repository (**Chubánov and Gudermann, 2016**). (1) Statistical analysis of metabolite measurements in serum samples. (2) Statistical analysis of metabolite measurements in gastrocnemius muscle samples. (3) Statistical analysis of metabolite measurements in liver samples. (4) Metabolites significantly changed in serum samples of *Trpm6*-deficient mice (FDR $p \leq 0.05$). (5) Metabolites significantly changed in gastrocnemius muscle samples of *Trpm6*-deficient mice (FDR $p \leq 0.05$). (6) Metabolites significantly changed in liver samples of *Trpm6*-deficient mice (FDR $p \leq 0.05$). (7) Abbreviations of metabolites.

DOI: [10.7554/eLife.20914.024](https://doi.org/10.7554/eLife.20914.024)

Major datasets

The following datasets were generated:

Author(s)	Year	Dataset title	Dataset URL	Database, license, and accessibility information
Chubánov V, Gudermann T	2015	Whole-genome profiling of the liver transcriptome in <i>Trpm6</i> gene deficient mice and control littermates	https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70457	Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE70457)
Chubánov V, Gudermann T	2016	Data from: Epithelial magnesium transport by TRPM6 is essential for prenatal development and adult survival	http://dx.doi.org/10.5061/dryad.gs7fv	Available at Dryad Digital Repository under a CC0 Public Domain Dedication

References

- Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, Cerwinski W, MacDonald JF, Tymianski M. 2003. A key role for TRPM7 channels in anoxic neuronal death. *Cell* **115**:863–877. doi: [10.1016/S0092-8674\(03\)01017-1](https://doi.org/10.1016/S0092-8674(03)01017-1), PMID: [14697204](https://pubmed.ncbi.nlm.nih.gov/14697204/)
- Abraham KJ, Chan JN, Salvi JS, Ho B, Hall A, Vidya E, Guo R, Killackey SA, Liu N, Lee JE, Brown GW, Mekhail K. 2016. Intersection of calorie restriction and magnesium in the suppression of genome-destabilizing RNA-DNA hybrids. *Nucleic Acids Research* **44**:8870–8884. doi: [10.1093/nar/gkw752](https://doi.org/10.1093/nar/gkw752), PMID: [27574117](https://pubmed.ncbi.nlm.nih.gov/27574117/)
- Bartke A, Sun LY, Longo V. 2013. Somatotropic signaling: trade-offs between growth, reproductive development, and longevity. *Physiological Reviews* **93**:571–598. doi: [10.1152/physrev.00006.2012](https://doi.org/10.1152/physrev.00006.2012), PMID: [23589828](https://pubmed.ncbi.nlm.nih.gov/23589828/)
- Blomen VA, Májek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J, Sacco R, van Diemen FR, Olk N, Stukalov A, Marceau C, Janssen H, Carette JE, Bennett KL, Colinge J, Superti-Furga G, Brummelkamp TR. 2015. Gene essentiality and synthetic lethality in haploid human cells. *Science* **350**:1092–1096. doi: [10.1126/science.aac7557](https://doi.org/10.1126/science.aac7557), PMID: [26472760](https://pubmed.ncbi.nlm.nih.gov/26472760/)
- Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. 2004. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. *Molecular Aspects of Medicine* **25**:495–520. doi: [10.1016/j.mam.2004.06.004](https://doi.org/10.1016/j.mam.2004.06.004), PMID: [15363638](https://pubmed.ncbi.nlm.nih.gov/15363638/)
- Brandao K, Deason-Towne F, Perraud AL, Schmitz C. 2013. The role of Mg²⁺ in immune cells. *Immunologic Research* **55**:261–269. doi: [10.1007/s12026-012-8371-x](https://doi.org/10.1007/s12026-012-8371-x), PMID: [22990458](https://pubmed.ncbi.nlm.nih.gov/22990458/)
- Braun A, Gessner JE, Varga-Szabo D, Syed SN, Konrad S, Stegner D, Vögtle T, Schmidt RE, Nieswandt B. 2009. STIM1 is essential for fcgamma receptor activation and autoimmune inflammation. *Blood* **113**:1097–1104. doi: [10.1182/blood-2008-05-158477](https://doi.org/10.1182/blood-2008-05-158477), PMID: [18941110](https://pubmed.ncbi.nlm.nih.gov/18941110/)
- Chaigne-Delalande B, Li FY, O'Connor GM, Lukacs MJ, Jiang P, Zheng L, Shatzer A, Biancalana M, Pittaluga S, Matthews HF, Jancel TJ, Blesing JJ, Marsh RA, Kuijpers TW, Nichols KE, Lucas CL, Nagpal S, Mehmet H, Su HC, Cohen JL, et al. 2013. Mg²⁺ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. *Science* **341**:186–191. doi: [10.1126/science.1240094](https://doi.org/10.1126/science.1240094), PMID: [23846901](https://pubmed.ncbi.nlm.nih.gov/23846901/)
- Chubánov V, Gudermann T. 2016. Data from: Epithelial magnesium transport by TRPM6 is essential for prenatal development and adult survival. *Dryad Digital Repository*. doi: [10.5061/dryad.gs7fv](https://doi.org/10.5061/dryad.gs7fv)
- Chubánov V, Waldegger S, Mederos y Schnitzler M, Vitzthum H, Sassen MC, Seyberth HW, Konrad M, Gudermann T. 2004. Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. *PNAS* **101**:2894–2899. doi: [10.1073/pnas.0305252101](https://doi.org/10.1073/pnas.0305252101), PMID: [14976260](https://pubmed.ncbi.nlm.nih.gov/14976260/)
- Dawson PA, Rakoczy J, Simmons DG. 2012. Placental, renal, and ileal sulfate transporter gene expression in mouse gestation. *Biology of Reproduction* **87**:43. doi: [10.1095/biolreprod.111.098749](https://doi.org/10.1095/biolreprod.111.098749), PMID: [22674389](https://pubmed.ncbi.nlm.nih.gov/22674389/)

- de Baaij JH, Hoenderop JG, Bindels RJ. 2015. Magnesium in man: implications for health and disease. *Physiological Reviews* **95**:1–46. doi: [10.1152/physrev.00012.2014](https://doi.org/10.1152/physrev.00012.2014), PMID: 25540137
- Ding F, O'Donnell J, Xu Q, Kang N, Goldman N, Nedergaard M. 2016. Changes in the composition of brain interstitial ions control the sleep-wake cycle. *Science* **352**:550–555. doi: [10.1126/science.aad4821](https://doi.org/10.1126/science.aad4821), PMID: 27126038
- Durlach J, Pagès N, Bac P, Bara M, Guiet-Bara A. 2004. New data on the importance of gestational mg deficiency. *Journal of the American College of Nutrition* **17**:116–125. doi: [10.1080/07315724.2004.10719411](https://doi.org/10.1080/07315724.2004.10719411), PMID: 15319145
- Erlebacher A, Price KA, Glimcher LH. 2004. Maintenance of mouse trophoblast stem cell proliferation by TGF-beta/activin. *Developmental Biology* **275**:158–169. doi: [10.1016/j.ydbio.2004.07.032](https://doi.org/10.1016/j.ydbio.2004.07.032), PMID: 15464579
- Essletzbichler P, Konopka T, Santoro F, Chen D, Gapp BV, Kralovics R, Brummelkamp TR, Nijman SM, Bürckstümmer T. 2014. Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line. *Genome Research* **24**:2059–2065. doi: [10.1101/gr.177220.114](https://doi.org/10.1101/gr.177220.114), PMID: 25373145
- Feeney KA, Hansen LL, Putker M, Olivares-Yañez C, Day J, Eades LJ, Larrondo LF, Hoyle NP, O'Neill JS, van Ooijen G. 2016. Daily magnesium fluxes regulate cellular timekeeping and energy balance. *Nature* **532**:375–379. doi: [10.1038/nature17407](https://doi.org/10.1038/nature17407), PMID: 27074515
- Fleig A, Chubanov V. 2014. TRPM7. *Handbook of experimental pharmacology* **222**:521–546. doi: [10.1007/978-3-642-54215-2_21](https://doi.org/10.1007/978-3-642-54215-2_21), PMID: 24756720
- Friedman M, Hatcher G, Watson L. 1967. Primary hypomagnesaemia with secondary hypocalcaemia in an infant. *The Lancet* **1**:703–705. doi: [10.1016/S0140-6736\(67\)92181-2](https://doi.org/10.1016/S0140-6736(67)92181-2), PMID: 4163945
- Garinis GA, Uittenboogaard LM, Stachelscheid H, Foustier M, van Ijcken W, Breit TM, van Steeg H, Mullenders LH, van der Horst GT, Brüning JC, Niessen CM, Hoeijmakers JH, Schumacher B. 2009. Persistent transcription-blocking DNA lesions trigger somatic growth attenuation associated with longevity. *Nature Cell Biology* **11**:604–615. doi: [10.1038/ncb1866](https://doi.org/10.1038/ncb1866), PMID: 19363488
- Gempel K, Kiechl S, Hofmann S, Lochmüller H, Kiechl-Kohlendorfer U, Willeit J, Sperl W, Rettinger A, Bieger I, Pongratz D, Gerbitz KD, Bauer MF. 2002. Screening for carnitine palmitoyltransferase II deficiency by tandem mass spectrometry. *Journal of Inherited Metabolic Disease* **25**:17–27. doi: [10.1023/A:1015109127986](https://doi.org/10.1023/A:1015109127986), PMID: 11999976
- Günther T. 2006. Concentration, compartmentation and metabolic function of intracellular free Mg²⁺. *Magnesium Research* **19**:225–236. PMID: 17402290
- Hayashi S, Tenzen T, McMahon AP. 2003. Maternal inheritance of cre activity in a Sox2Cre deleter strain. *Genesis* **37**:51–53. doi: [10.1002/gene.10225](https://doi.org/10.1002/gene.10225), PMID: 14595839
- Jin J, Desai BN, Navarro B, Donovan A, Andrews NC, Clapham DE. 2008. Deletion of Trpm7 disrupts embryonic development and thymopoiesis without altering Mg²⁺ homeostasis. *Science* **322**:756–760. doi: [10.1126/science.1163493](https://doi.org/10.1126/science.1163493), PMID: 18974357
- Jin J, Wu LJ, Jun J, Cheng X, Xu H, Andrews NC, Clapham DE. 2012. The channel kinase, TRPM7, is required for early embryonic development. *PNAS* **109**:E225–E233. doi: [10.1073/pnas.1120033109](https://doi.org/10.1073/pnas.1120033109), PMID: 22203997
- King DE, Mainous AG, Geesey ME, Woolson RF. 2005. Dietary magnesium and C-reactive protein levels. *Journal of the American College of Nutrition* **24**:166–171. doi: [10.1080/07315724.2005.10719461](https://doi.org/10.1080/07315724.2005.10719461), PMID: 15930481
- Konrad M, Schlingmann KP. 2014. Inherited disorders of renal hypomagnesaemia. *Nephrology Dialysis Transplantation* **29**:iv63–iv71. doi: [10.1093/ndt/gfu198](https://doi.org/10.1093/ndt/gfu198)
- Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, Hofer T, Seo AY, Sullivan R, Jobling WA, Morrow JD, Van Remmen H, Sedivy JM, Yamasoba T, Tanokura M, Weindruch R, Leeuwenburgh C, Prolla TA. 2005. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. *Science* **309**:481–484. doi: [10.1126/science.1112125](https://doi.org/10.1126/science.1112125), PMID: 16020738
- Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. 1997. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. *Nature* **390**:45–51. doi: [10.1038/36285](https://doi.org/10.1038/36285), PMID: 9363890
- Li FY, Chaigne-Delalande B, Kanellopoulou C, Davis JC, Matthews HF, Douek DC, Cohen JI, Uzel G, Su HC, Lenardo MJ. 2011. Second messenger role for Mg²⁺ revealed by human T-cell immunodeficiency. *Nature* **475**:471–476. doi: [10.1038/nature10246](https://doi.org/10.1038/nature10246), PMID: 21796205
- Lipman RD, Dallal GE, Bronson RT. 1999. Lesion biomarkers of aging in B6C3F1 hybrid mice. *The Journals of Gerontology Series A : Biological Sciences and Medical Sciences* **54**:B466–B477. doi: [10.1093/gerona/54.11.B466](https://doi.org/10.1093/gerona/54.11.B466)
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. 2013. The hallmarks of aging. *Cell* **153**:1194–1217. doi: [10.1016/j.cell.2013.05.039](https://doi.org/10.1016/j.cell.2013.05.039), PMID: 23746838
- Madison BB, Dunbar L, Qiao XT, Braunstein K, Braunstein E, Gumucio DL. 2002. Cis elements of the Villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. *Journal of Biological Chemistry* **277**:33275–33283. doi: [10.1074/jbc.M204935200](https://doi.org/10.1074/jbc.M204935200), PMID: 12065599
- Maier JA. 2012. Endothelial cells and magnesium: implications in atherosclerosis. *Clinical Science* **122**:397–407. doi: [10.1042/CS20110506](https://doi.org/10.1042/CS20110506), PMID: 22248353
- Mariño G, Ugalde AP, Fernández AF, Osorio FG, Fueyo A, Freije JM, López-Otín C. 2010. Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function. *PNAS* **107**:16268–16273. doi: [10.1073/pnas.1002696107](https://doi.org/10.1073/pnas.1002696107), PMID: 20805469
- Milla PJ, Aggett PJ, Wolff OH, Harries JT. 1979. Studies in primary hypomagnesaemia: evidence for defective carrier-mediated small intestinal transport of magnesium. *Gut* **20**:1028–1033. doi: [10.1136/gut.20.11.1028](https://doi.org/10.1136/gut.20.11.1028), PMID: 527871

- Miller RA**, Harrison DE, Astle CM, Floyd RA, Flurkey K, Hensley KL, Javors MA, Leeuwenburgh C, Nelson JF, Ongini E, Nadon NL, Warner HR, Strong R. 2007. An aging interventions testing program: study design and interim report. *Aging Cell* **6**:565–575. doi: [10.1111/j.1474-9726.2007.00311.x](https://doi.org/10.1111/j.1474-9726.2007.00311.x), PMID: [17578509](https://pubmed.ncbi.nlm.nih.gov/17578509/)
- Mitchell SJ**, Madrigal-Matute J, Scheibye-Knudsen M, Fang E, Aon M, González-Reyes JA, Cortassa S, Kaushik S, Gonzalez-Freire M, Patel B, Wahl D, Ali A, Calvo-Rubio M, Burón MI, Guitierrez V, Ward TM, Palacios HH, Cai H, Frederick DW, Hine C, et al. 2016. Effects of sex, strain, and energy intake on hallmarks of aging in mice. *Cell Metabolism* **23**:1093–1112. doi: [10.1016/j.cmet.2016.05.027](https://doi.org/10.1016/j.cmet.2016.05.027), PMID: [27304509](https://pubmed.ncbi.nlm.nih.gov/27304509/)
- Mostoslavsky R**, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, Liu P, Mostoslavsky G, Franco S, Murphy MM, Mills KD, Patel P, Hsu JT, Hong AL, Ford E, Cheng HL, Kennedy C, Nunez N, Bronson R, Frendewey D, et al. 2006. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. *Cell* **124**:315–329. doi: [10.1016/j.cell.2005.11.044](https://doi.org/10.1016/j.cell.2005.11.044), PMID: [16439206](https://pubmed.ncbi.nlm.nih.gov/16439206/)
- Nadler MJ**, Hermosura MC, Inabe K, Perraud AL, Zhu Q, Stokes AJ, Kurosaki T, Kinet JP, Penner R, Scharenberg AM, Fleig A. 2001. LTRPC7 is a Mg²⁺-ATP-regulated divalent cation channel required for cell viability. *Nature* **411**:590–595. doi: [10.1038/35079092](https://doi.org/10.1038/35079092), PMID: [11385574](https://pubmed.ncbi.nlm.nih.gov/11385574/)
- Natale DR**, Hemberger M, Hughes M, Cross JC. 2009. Activin promotes differentiation of cultured mouse trophoblast stem cells towards a labyrinth cell fate. *Developmental Biology* **335**:120–131. doi: [10.1016/j.ydbio.2009.08.022](https://doi.org/10.1016/j.ydbio.2009.08.022), PMID: [19716815](https://pubmed.ncbi.nlm.nih.gov/19716815/)
- Niedernhofer LJ**, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E, Odiijk H, Oostendorp R, Ahmad A, van Leeuwen W, Theil AF, Vermeulen W, van der Horst GT, Meinecke P, Kleijer WJ, Vijg J, Jaspers NG, Hoeijmakers JH. 2006. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. *Nature* **444**:1038–1043. doi: [10.1038/nature05456](https://doi.org/10.1038/nature05456), PMID: [17183314](https://pubmed.ncbi.nlm.nih.gov/17183314/)
- Nörenberg W**, Plötz T, Sobottka H, Chubanov V, Mittermeier L, Kalwa H, Aigner A, Schaefer M. 2016. TRPM7 is a molecular substrate of ATP-evoked P2X7-like currents in tumor cells. *The Journal of General Physiology* **147**:467–483. doi: [10.1085/jgp.201611595](https://doi.org/10.1085/jgp.201611595), PMID: [27185858](https://pubmed.ncbi.nlm.nih.gov/27185858/)
- Palacios-Prado N**, Chapuis S, Panjkovich A, Fregeac J, Nagy JI, Bukauskas FF. 2014. Molecular determinants of magnesium-dependent synaptic plasticity at electrical synapses formed by connexin36. *Nature Communications* **5**:4667. doi: [10.1038/ncomms5667](https://doi.org/10.1038/ncomms5667), PMID: [25135336](https://pubmed.ncbi.nlm.nih.gov/25135336/)
- Pena MJ**, Lambers Heerspink HJ, Hellemons ME, Friedrich T, Dallmann G, Lajer M, Bakker SJ, Gansevoort RT, Rossing P, de Zeeuw D, Roscioni SS. 2014. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with type 2 diabetes mellitus. *Diabetic Medicine* **31**:1138–1147. doi: [10.1111/dme.12447](https://doi.org/10.1111/dme.12447), PMID: [24661264](https://pubmed.ncbi.nlm.nih.gov/24661264/)
- Pesta D**, Gnaiger E. 2012. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. *Methods in Molecular Biology* **810**:25–58. doi: [10.1007/978-1-61779-382-0_3](https://doi.org/10.1007/978-1-61779-382-0_3), PMID: [22057559](https://pubmed.ncbi.nlm.nih.gov/22057559/)
- Quamme GA**. 2010. Molecular identification of ancient and modern mammalian magnesium transporters. *American Journal of Physiology: Cell Physiology* **298**:C407–429. doi: [10.1152/ajpcell.00124.2009](https://doi.org/10.1152/ajpcell.00124.2009), PMID: [19940067](https://pubmed.ncbi.nlm.nih.gov/19940067/)
- Ritchie ME**, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research* **43**:e47. doi: [10.1093/nar/gkv007](https://doi.org/10.1093/nar/gkv007), PMID: [25605792](https://pubmed.ncbi.nlm.nih.gov/25605792/)
- Rodushkin I**, Engström E, Stenberg A, Baxter DC. 2004. Determination of low-abundance elements at ultra-trace levels in urine and serum by inductively coupled plasma-sector field mass spectrometry. *Analytical and Bioanalytical Chemistry* **380**:247–257. doi: [10.1007/s00216-004-2742-7](https://doi.org/10.1007/s00216-004-2742-7), PMID: [15322793](https://pubmed.ncbi.nlm.nih.gov/15322793/)
- Rodushkin I**, Odman F. 2001. Application of inductively coupled plasma sector field mass spectrometry for elemental analysis of urine. *Journal of Trace Elements in Medicine and Biology* **14**:241–247. doi: [10.1016/S0946-672X\(01\)80010-9](https://doi.org/10.1016/S0946-672X(01)80010-9), PMID: [11396785](https://pubmed.ncbi.nlm.nih.gov/11396785/)
- Romani AM**. 2011. Cellular magnesium homeostasis. *Archives of Biochemistry and Biophysics* **512**:1–23. doi: [10.1016/j.abb.2011.05.010](https://doi.org/10.1016/j.abb.2011.05.010), PMID: [21640700](https://pubmed.ncbi.nlm.nih.gov/21640700/)
- Rosanoff A**, Weaver CM, Rude RK. 2012. Suboptimal magnesium status in the United States: are the health consequences underestimated? *Nutrition Reviews* **70**:153–164. doi: [10.1111/j.1753-4887.2011.00465.x](https://doi.org/10.1111/j.1753-4887.2011.00465.x), PMID: [22364157](https://pubmed.ncbi.nlm.nih.gov/22364157/)
- Ryazanova LV**, Rondon LJ, Zierler S, Hu Z, Galli J, Yamaguchi TP, Mazur A, Fleig A, Ryazanov AG. 2010. TRPM7 is essential for Mg²⁺ homeostasis in mammals. *Nature Communications* **1**:109. doi: [10.1038/ncomms1108](https://doi.org/10.1038/ncomms1108), PMID: [21045827](https://pubmed.ncbi.nlm.nih.gov/21045827/)
- Saggerson ED**. 1982. Carnitine acyltransferase activities in rat liver and heart measured with palmitoyl-CoA and octanoyl-CoA. latency, effects of K⁺, bivalent metal ions and malonyl-CoA. *Biochemical Journal* **202**:397–405. doi: [10.1042/bj2020397](https://doi.org/10.1042/bj2020397), PMID: [7092822](https://pubmed.ncbi.nlm.nih.gov/7092822/)
- Sah R**, Mesirca P, Mason X, Gibson W, Bates-Withers C, Van den Boogert M, Chaudhuri D, Pu WT, Mangoni ME, Clapham DE. 2013. Timing of myocardial TRPM7 deletion during cardiogenesis variably disrupts adult ventricular function, conduction, and repolarization. *Circulation* **128**:101–114. doi: [10.1161/CIRCULATIONAHA.112.000768](https://doi.org/10.1161/CIRCULATIONAHA.112.000768), PMID: [23734001](https://pubmed.ncbi.nlm.nih.gov/23734001/)
- Saraç M**, Önalın E, Bakal Ü, Tartar T, Aydın M, Orman A, Tektemur A, Taşkın E, Erol FS, Kazez A. 2016. Magnesium-permeable TRPM6 polymorphisms in patients with meningomyelocele. *SpringerPlus* **5**:1703. doi: [10.1186/s40064-016-3395-7](https://doi.org/10.1186/s40064-016-3395-7), PMID: [27757375](https://pubmed.ncbi.nlm.nih.gov/27757375/)
- Schlingmann KP**, Sassen MC, Weber S, Pechmann U, Kusch K, Pelken L, Lotan D, Syrrou M, Prebble JJ, Cole DE, Metzger DL, Rahman S, Tajima T, Shu SG, Waldegger S, Seyberth HW, Konrad M. 2005. Novel TRPM6

- mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia. *Journal of the American Society of Nephrology* **16**:3061–3069. doi: [10.1681/ASN.2004110989](https://doi.org/10.1681/ASN.2004110989), PMID: [16107578](https://pubmed.ncbi.nlm.nih.gov/16107578/)
- Schlingmann KP**, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, Kratz M, Haddad E, Ristoff E, Dinour D, Syrrou M, Nielsen S, Sassen M, Waldegger S, Seyberth HW, Konrad M. 2002. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. *Nature Genetics* **31**:166–170. doi: [10.1038/ng889](https://doi.org/10.1038/ng889), PMID: [12032568](https://pubmed.ncbi.nlm.nih.gov/12032568/)
- Schmitz C**, Perraud AL, Johnson CO, Inabe K, Smith MK, Penner R, Kurosaki T, Fleig A, Scharenberg AM. 2003. Regulation of vertebrate cellular Mg²⁺ homeostasis by TRPM7. *Cell* **114**:191–200. doi: [10.1016/S0092-8674\(03\)00556-7](https://doi.org/10.1016/S0092-8674(03)00556-7), PMID: [12887921](https://pubmed.ncbi.nlm.nih.gov/12887921/)
- Schulz S**, Lichtmannegger J, Schmitt S, Leitzinger C, Eberhagen C, Einer C, Kerth J, Aichler M, Zischka H. 2015. A protocol for the parallel isolation of intact mitochondria from rat liver, kidney, heart, and brain. *Methods in Molecular Biology* **1295**:75–86. doi: [10.1007/978-1-4939-2550-6_7](https://doi.org/10.1007/978-1-4939-2550-6_7), PMID: [25820715](https://pubmed.ncbi.nlm.nih.gov/25820715/)
- Schulz S**, Schmitt S, Wimmer R, Aichler M, Eisenhofer S, Lichtmannegger J, Eberhagen C, Artmann R, Tookos F, Walch A, Krappmann D, Brenner C, Rust C, Zischka H. 2013. Progressive stages of mitochondrial destruction caused by cell toxic bile salts. *Biochimica Et Biophysica Acta - Biomembranes* **1828**:2121–2133. doi: [10.1016/j.bbamem.2013.05.007](https://doi.org/10.1016/j.bbamem.2013.05.007)
- Schumacher B**, van der Pluijm I, Moorhouse MJ, Kosteas T, Robinson AR, Suh Y, Breit TM, van Steeg H, Niedernhofer LJ, van Ijcken W, Bartke A, Spindler SR, Hoeijmakers JH, van der Horst GT, Garinis GA. 2008. Delayed and accelerated aging share common longevity assurance mechanisms. *PLoS Genetics* **4**:e1000161. doi: [10.1371/journal.pgen.1000161](https://doi.org/10.1371/journal.pgen.1000161), PMID: [18704162](https://pubmed.ncbi.nlm.nih.gov/18704162/)
- Shao X**, Somlo S, Igarashi P. 2002. Epithelial-specific cre/lox recombination in the developing kidney and genitourinary tract. *Journal of the American Society of Nephrology* **13**:1837–1846. doi: [10.1097/01.ASN.0000016444.90348.50](https://doi.org/10.1097/01.ASN.0000016444.90348.50), PMID: [12089379](https://pubmed.ncbi.nlm.nih.gov/12089379/)
- Simmons DG**, Cross JC. 2005. Determinants of trophoblast lineage and cell subtype specification in the mouse placenta. *Developmental Biology* **284**:12–24. doi: [10.1016/j.ydbio.2005.05.010](https://doi.org/10.1016/j.ydbio.2005.05.010), PMID: [15963972](https://pubmed.ncbi.nlm.nih.gov/15963972/)
- Simmons DG**, Natale DR, Begay V, Hughes M, Leutz A, Cross JC. 2008. Early patterning of the chorion leads to the trilaminar trophoblast cell structure in the placental labyrinth. *Development* **135**:2083–2091. doi: [10.1242/dev.020099](https://doi.org/10.1242/dev.020099), PMID: [18448564](https://pubmed.ncbi.nlm.nih.gov/18448564/)
- Smyth GK**. 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Statistical Applications in Genetics and Molecular Biology* **3**:1–25. doi: [10.2202/1544-6115.1027](https://doi.org/10.2202/1544-6115.1027)
- Springer ML**, Rando T, Blau HM. 2002. Gene delivery to muscle. Boyle AL *Current Protocols in Human Genetics*. New York: John Wiley & Sons. doi: [10.1002/0471142905.hg1304s31](https://doi.org/10.1002/0471142905.hg1304s31)
- Stritt S**, Nurden P, Favier R, Favier M, Ferioli S, Gotru SK, van Eeuwijk JM, Schulze H, Nurden AT, Lambert MP, Turro E, Burger-Stritt S, Matsushita M, Mittermeier L, Ballerini P, Zierler S, Laffan MA, Chubonov V, Gudermann T, Nieswandt B, et al. 2016. Defects in TRPM7 channel function deregulate thrombopoiesis through altered cellular Mg(2+) homeostasis and cytoskeletal architecture. *Nature Communications* **7**:11097. doi: [10.1038/ncomms11097](https://doi.org/10.1038/ncomms11097), PMID: [27020697](https://pubmed.ncbi.nlm.nih.gov/27020697/)
- Tanaka S**, Kunath T, Hadjantonakis AK, Nagy A, Rossant J. 1998. Promotion of trophoblast stem cell proliferation by FGF4. *Science* **282**:2072–2075. doi: [10.1126/science.282.5396.2072](https://doi.org/10.1126/science.282.5396.2072), PMID: [9851926](https://pubmed.ncbi.nlm.nih.gov/9851926/)
- Tin A**, Köttgen A, Folsom AR, Maruthur NM, Tajuddin SM, Nalls MA, Evans MK, Zonderman AB, Friedrich CA, Boerwinkle E, Coresh J, Kao WH. 2015. Genetic loci for serum magnesium among African-Americans and gene-environment interaction at MUC1 and TRPM6 in European-Americans: the atherosclerosis risk in communities (ARIC) study. *BMC Genetics* **16**:56. doi: [10.1186/s12863-015-0219-7](https://doi.org/10.1186/s12863-015-0219-7), PMID: [26058915](https://pubmed.ncbi.nlm.nih.gov/26058915/)
- Trifunovic A**, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, Bohlooly-Y M, Gidlöf S, Oldfors A, Wibom R, Törnell J, Jacobs HT, Larsson NG. 2004. Premature ageing in mice expressing defective mitochondrial DNA polymerase. *Nature* **429**:417–423. doi: [10.1038/nature02517](https://doi.org/10.1038/nature02517), PMID: [15164064](https://pubmed.ncbi.nlm.nih.gov/15164064/)
- Turturro A**, Witt WW, Lewis S, Hass BS, Lipman RD, Hart RW. 1999. Growth curves and survival characteristics of the animals used in the biomarkers of aging program. *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences* **54**:B492–501. doi: [10.1093/gerona/54.11.B492](https://doi.org/10.1093/gerona/54.11.B492), PMID: [10619312](https://pubmed.ncbi.nlm.nih.gov/10619312/)
- van de Ven M**, Andressoo JO, Holcomb VB, von Lindern M, Jong WM, De Zeeuw CI, Suh Y, Hasty P, Hoeijmakers JH, van der Horst GT, Mitchell JR. 2006. Adaptive stress response in segmental progeria resembles long-lived dwarfism and calorie restriction in mice. *PLoS Genetics* **2**:e192. doi: [10.1371/journal.pgen.0020192](https://doi.org/10.1371/journal.pgen.0020192), PMID: [17173483](https://pubmed.ncbi.nlm.nih.gov/17173483/)
- van der Pluijm I**, Garinis GA, Brandt RM, Gorgels TG, Wijnhoven SW, Diderich KE, de Wit J, Mitchell JR, van Oostrom C, Beems R, Niedernhofer LJ, Velasco S, Friedberg EC, Tanaka K, van Steeg H, Hoeijmakers JH, van der Horst GT. 2007. Impaired genome maintenance suppresses the growth hormone–insulin-like growth factor 1 axis in mice with Cockayne syndrome. *PLoS Biology* **5**:e2. doi: [10.1371/journal.pbio.0050002](https://doi.org/10.1371/journal.pbio.0050002), PMID: [17326724](https://pubmed.ncbi.nlm.nih.gov/17326724/)
- van der Vorst EP**, Jeurissen M, Wolfs IM, Keijbeck A, Theodorou K, Wijnands E, Schurgers L, Weber S, Gijbels MJ, Hamers AA, Dreymueller D, Rose-John S, de Winther MP, Ludwig A, Saftig P, Biessen EA, Donners MM. 2015. Myeloid A disintegrin and metalloproteinase domain 10 deficiency modulates atherosclerotic plaque composition by shifting the balance from inflammation toward fibrosis. *The American Journal of Pathology* **185**:1145–1155. doi: [10.1016/j.ajpath.2014.11.028](https://doi.org/10.1016/j.ajpath.2014.11.028), PMID: [25659879](https://pubmed.ncbi.nlm.nih.gov/25659879/)
- Varela I**, Cadiñanos J, Pendás AM, Gutiérrez-Fernández A, Folgueras AR, Sánchez LM, Zhou Z, Rodríguez FJ, Stewart CL, Vega JA, Tryggvason K, Freije JM, López-Otín C. 2005. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. *Nature* **437**:564–568. doi: [10.1038/nature04019](https://doi.org/10.1038/nature04019), PMID: [16079796](https://pubmed.ncbi.nlm.nih.gov/16079796/)

- Voets T**, Nilius B, Hoefs S, van der Kemp AW, Droogmans G, Bindels RJ, Hoenderop JG. 2004. TRPM6 forms the Mg²⁺ influx channel involved in intestinal and renal Mg²⁺ absorption. *Journal of Biological Chemistry* **279**:19–25. doi: [10.1074/jbc.M311201200](https://doi.org/10.1074/jbc.M311201200), PMID: [14576148](https://pubmed.ncbi.nlm.nih.gov/14576148/)
- Walder RY**, Landau D, Meyer P, Shalev H, Tsolia M, Borochowitz Z, Boettger MB, Beck GE, Englehardt RK, Carmi R, Sheffield VC. 2002. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. *Nature Genetics* **31**:171–174. doi: [10.1038/ng901](https://doi.org/10.1038/ng901), PMID: [12032570](https://pubmed.ncbi.nlm.nih.gov/12032570/)
- Walder RY**, Yang B, Stokes JB, Kirby PA, Cao X, Shi P, Searby CC, Husted RF, Sheffield VC. 2009. Mice defective in TRPM6 show embryonic mortality and neural tube defects. *Human Molecular Genetics* **18**:4367–4375. doi: [10.1093/hmg/ddp392](https://doi.org/10.1093/hmg/ddp392), PMID: [19692351](https://pubmed.ncbi.nlm.nih.gov/19692351/)
- Wang T**, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, Lander ES, Sabatini DM. 2015. Identification and characterization of essential genes in the human genome. *Science* **350**:1096–1101. doi: [10.1126/science.aac7041](https://doi.org/10.1126/science.aac7041), PMID: [26472758](https://pubmed.ncbi.nlm.nih.gov/26472758/)
- Woudenberg-Vrenken TE**, Sukinta A, van der Kemp AW, Bindels RJ, Hoenderop JG. 2011. Transient receptor potential melastatin 6 knockout mice are lethal whereas heterozygous deletion results in mild hypomagnesemia. *Nephron Physiology* **117**:11–19. doi: [10.1159/000320580](https://doi.org/10.1159/000320580), PMID: [20814221](https://pubmed.ncbi.nlm.nih.gov/20814221/)
- Zhang Y**, Xu J, Ruan YC, Yu MK, O’Laughlin M, Wise H, Chen D, Tian L, Shi D, Wang J, Chen S, Feng JQ, Chow DH, Xie X, Zheng L, Huang L, Huang S, Leung K, Lu N, Zhao L, et al. 2016. Implant-derived magnesium induces local neuronal production of CGRP to improve bone-fracture healing in rats. *Nature Medicine* **22**:1160–1169. doi: [10.1038/nm.4162](https://doi.org/10.1038/nm.4162), PMID: [27571347](https://pubmed.ncbi.nlm.nih.gov/27571347/)
- Zhang Z**, Yu H, Huang J, Faouzi M, Schmitz C, Penner R, Fleig A. 2014. The TRPM6 kinase domain determines the mg-ATP sensitivity of TRPM7/M6 heteromeric ion channels. *Journal of Biological Chemistry* **289**:5217–5227. doi: [10.1074/jbc.M113.512285](https://doi.org/10.1074/jbc.M113.512285), PMID: [24385424](https://pubmed.ncbi.nlm.nih.gov/24385424/)
- Zhou H**, Clapham DE. 2009. Mammalian MagT1 and TUSC3 are required for cellular magnesium uptake and vertebrate embryonic development. *PNAS* **106**:15750–15755. doi: [10.1073/pnas.0908332106](https://doi.org/10.1073/pnas.0908332106), PMID: [19717468](https://pubmed.ncbi.nlm.nih.gov/19717468/)
- Zischka H**, Lichtmannegger J, Schmitt S, Jägemann N, Schulz S, Wartini D, Jennen L, Rust C, Larochette N, Galluzzi L, Chajes V, Bandow N, Gilles VS, DiSpirito AA, Esposito I, Goettlicher M, Summer KH, Kroemer G. 2011. Liver mitochondrial membrane crosslinking and destruction in a rat model of wilson disease. *Journal of Clinical Investigation* **121**:1508–1518. doi: [10.1172/JCI45401](https://doi.org/10.1172/JCI45401), PMID: [21364284](https://pubmed.ncbi.nlm.nih.gov/21364284/)